Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
amyloid-beta + H2O
?
the enzyme has two distinctive binding sites for two different substrates. Amyloid-beta degradation occurs through S1 pocket but not through S1' pocket responsible for hydrolysis of N-acetyl-L-aspartyl-L-glutamate. Pre-incubation with N-acetyl-L-aspartyl-L-glutamate and amyloid-beta does not affect amyloid-beta degradation and hydrolysis of N-acetyl-L-aspartyl-L-glutamate, respectively
-
-
?
folyl-(gamma-L-glutamic acid)2 + H2O
folyl-gamma-L-glutamic acid + L-glutamate
-
-
-
?
folyl-(gamma-L-glutamic acid)3 + H2O
folyl-(gamma-L-glutamic acid)2 + L-glutamate
-
-
-
?
folyl-(gamma-L-glutamic acid)4 + H2O
folyl-(gamma-L-glutamic acid)3 + L-glutamate
-
-
-
?
folyl-gamma-L-glutamic acid + H2O
folate + L-glutamate
-
-
-
?
folyl-poly-gamma-glutamate + H2O
?
-
cleavage of the C-terminal glutamate
-
-
?
gamma-L-Glu-L-Glu + H2O
L-Glu + L-Glu
-
-
-
-
?
L-Asp-L-Glu + H2O
L-Asp + L-Glu
-
-
-
-
?
L-Glu-L-Glu + H2O
L-Glu + L-Glu
-
-
-
-
?
methotrexate triglutamate + H2O
L-Glu + methotrexate
-
-
-
?
N-acetyl-alpha L-aspartyl-L-glutamate + H2O
N-acetyl-L-aspartate + L-glutamate
-
-
-
-
?
N-acetyl-alpha-L-aspartyl-L-glutamate + H2O
N-acetyl-alpha-L-aspartate + L-glutamate
N-acetyl-Asp-Glu + H2O
N-acetyl-Asp + Glu
N-Acetyl-L-Asp-L-Glu + H2O
?
N-Acetyl-L-Asp-L-Glu + H2O
N-Acetyl-L-Asp + L-Glu
N-acetyl-L-aspartyl-L-glutamate
N-acetyl-L-aspartate + L-glutamate
-
-
-
?
N-acetyl-L-aspartyl-L-glutamate + H2O
L-glutamate + N-acetyl-L-aspartate
N-acetyl-L-aspartyl-L-glutamate + H2O
N-acetyl-L-Asp + L-Glu
N-acetyl-L-aspartyl-L-glutamate + H2O
N-acetyl-L-aspartate + L-glutamate
N-[4-(phenylazo)-benzoyl]-L-glutamyl-gamma-L-glutamic acid + H2O
?
-
-
-
-
?
poly-gamma-glutamate folate + H2O
?
poly-gamma-Glutamylfolate + H2O
L-Glu + gamma-glutamylfolate
-
-
removes sequentially gamma-linked glutamates
?
pteroyl-di-L-glutamate + H2O
L-Glu + pteroylglutamate
pteroylpentaglutamate + H2O
L-Glu + pteroylglutamate
-
-
-
?
additional information
?
-
N-acetyl-alpha-L-aspartyl-L-glutamate + H2O
N-acetyl-alpha-L-aspartate + L-glutamate
-
-
-
-
?
N-acetyl-alpha-L-aspartyl-L-glutamate + H2O
N-acetyl-alpha-L-aspartate + L-glutamate
-
i.e. NAAG
-
-
?
N-acetyl-alpha-L-aspartyl-L-glutamate + H2O
N-acetyl-alpha-L-aspartate + L-glutamate
-
-
-
-
?
N-acetyl-alpha-L-aspartyl-L-glutamate + H2O
N-acetyl-alpha-L-aspartate + L-glutamate
-
-
-
?
N-acetyl-alpha-L-aspartyl-L-glutamate + H2O
N-acetyl-alpha-L-aspartate + L-glutamate
-
enantiospecific reaction
-
-
?
N-acetyl-alpha-L-aspartyl-L-glutamate + H2O
N-acetyl-alpha-L-aspartate + L-glutamate
-
i.e. NAAG, a neurodipeptide, the enzyme acts as membrane-bound receptor being recycled through clathrin coated pits, expression regulation within cells and involvement in prostate cancer and metastasis, overview
-
-
?
N-acetyl-alpha-L-aspartyl-L-glutamate + H2O
N-acetyl-alpha-L-aspartate + L-glutamate
-
supply of the primary excitatory neurotransmitter glutamate, the enzyme is involved in neurological disorders, and neuropathic and inflammatory pain
-
-
?
N-acetyl-alpha-L-aspartyl-L-glutamate + H2O
N-acetyl-alpha-L-aspartate + L-glutamate
-
the enzyme is involved in glutamate-mediated neurodegenerative disorders, enzyme inhibition is a mechanism for reduction of excitotoxic glutamate
-
-
?
N-acetyl-alpha-L-aspartyl-L-glutamate + H2O
N-acetyl-alpha-L-aspartate + L-glutamate
-
the enzyme is involved in suppressing prostate cancer invasiveness
-
-
?
N-acetyl-alpha-L-aspartyl-L-glutamate + H2O
N-acetyl-alpha-L-aspartate + L-glutamate
-
the enzyme is responsible for cleavage of NAAG to yield free glutamate
-
-
?
N-acetyl-alpha-L-aspartyl-L-glutamate + H2O
N-acetyl-alpha-L-aspartate + L-glutamate
the essential enzyme is involved in prostate cancer, stroke, amyotrophic lateral sclerosis, and neuropathic pain
-
-
?
N-acetyl-alpha-L-aspartyl-L-glutamate + H2O
N-acetyl-alpha-L-aspartate + L-glutamate
-
i.e. NAAG
-
-
?
N-acetyl-alpha-L-aspartyl-L-glutamate + H2O
N-acetyl-alpha-L-aspartate + L-glutamate
i.e. NAAG
-
-
?
N-acetyl-alpha-L-aspartyl-L-glutamate + H2O
N-acetyl-alpha-L-aspartate + L-glutamate
i.e. NAAG, C-terminal glutamate recognition
-
-
?
N-acetyl-alpha-L-aspartyl-L-glutamate + H2O
N-acetyl-alpha-L-aspartate + L-glutamate
-
-
-
-
?
N-acetyl-alpha-L-aspartyl-L-glutamate + H2O
N-acetyl-alpha-L-aspartate + L-glutamate
-
i.e. NAAG
-
-
?
N-acetyl-alpha-L-aspartyl-L-glutamate + H2O
N-acetyl-alpha-L-aspartate + L-glutamate
-
-
-
-
?
N-acetyl-alpha-L-aspartyl-L-glutamate + H2O
N-acetyl-alpha-L-aspartate + L-glutamate
-
i.e. NAAG
-
-
?
N-acetyl-alpha-L-aspartyl-L-glutamate + H2O
N-acetyl-alpha-L-aspartate + L-glutamate
-
-
-
-
?
N-acetyl-alpha-L-aspartyl-L-glutamate + H2O
N-acetyl-alpha-L-aspartate + L-glutamate
-
i.e. NAAG, a neurodipeptide, the enzyme acts as membrane-bound receptor being recycled through clathrin coated pits, expression regulation within cells in prostate cancer and metastasis, overview
-
-
?
N-acetyl-alpha-L-aspartyl-L-glutamate + H2O
N-acetyl-alpha-L-aspartate + L-glutamate
the enzyme inactivates the neurotransmitter in the synaptic cleft
-
-
?
N-acetyl-alpha-L-aspartyl-L-glutamate + H2O
N-acetyl-alpha-L-aspartate + L-glutamate
-
the enzyme is responsible for glutamate supply, enzyme inhibition decreases the glutamate and increases the N-acetyl-alpha-L-aspartyl-L-glutamate concentration in the brain, which can be a method to treat opioid tolerance and diminish effects of morphine withdrawal, overview
-
-
?
N-acetyl-alpha-L-aspartyl-L-glutamate + H2O
N-acetyl-alpha-L-aspartate + L-glutamate
-
i.e. NAAG
-
-
?
N-acetyl-alpha-L-aspartyl-L-glutamate + H2O
N-acetyl-alpha-L-aspartate + L-glutamate
i.e. NAAG
-
-
?
N-acetyl-alpha-L-aspartyl-L-glutamate + H2O
N-acetyl-alpha-L-aspartate + L-glutamate
-
the enzyme is responsible for glutamate supply, enzyme inhibition decreases the glutamate and increases the N-acetyl-alpha-L-aspartyl-L-glutamate concentration in the brain, which can be a method to treat opioid tolerance and diminish effects of morphine withdrawal, overview
-
-
?
N-acetyl-alpha-L-aspartyl-L-glutamate + H2O
N-acetyl-alpha-L-aspartate + L-glutamate
-
i.e. NAAG
-
-
?
N-acetyl-alpha-L-aspartyl-L-glutamate + H2O
N-acetyl-alpha-L-aspartate + L-glutamate
-
enzyme regulation is mediated by glial glutamate and acetylcholine receptors in the nervous tissue
-
-
?
N-acetyl-alpha-L-aspartyl-L-glutamate + H2O
N-acetyl-alpha-L-aspartate + L-glutamate
-
i.e. NAAG
-
-
?
N-acetyl-alpha-L-aspartyl-L-glutamate + H2O
N-acetyl-alpha-L-aspartate + L-glutamate
-
-
-
-
?
N-acetyl-alpha-L-aspartyl-L-glutamate + H2O
N-acetyl-alpha-L-aspartate + L-glutamate
-
enantiospecific reaction
-
-
?
N-acetyl-alpha-L-aspartyl-L-glutamate + H2O
N-acetyl-alpha-L-aspartate + L-glutamate
-
enzyme inhibition reduces acute neuronal degeneration and astrocyte damage following lateral fluid percussion traumatic brain injury
-
-
?
N-acetyl-alpha-L-aspartyl-L-glutamate + H2O
N-acetyl-alpha-L-aspartate + L-glutamate
-
i.e. NAAG, a neurodipeptide, the enzyme acts as membrane-bound receptor being recycled through clathrin coated pits, expression regulation within cells in prostate cancer and metastasis, overview
-
-
?
N-acetyl-alpha-L-aspartyl-L-glutamate + H2O
N-acetyl-alpha-L-aspartate + L-glutamate
-
i.e. NAAG, a presynaptically active endogenous neuropeptide which is cleaved by the enzyme in the extracellular space
-
-
?
N-acetyl-alpha-L-aspartyl-L-glutamate + H2O
N-acetyl-alpha-L-aspartate + L-glutamate
-
NAAG peptidase inhibitor reduces acute neuronal degeneration and astrocyte damage following lateral fluid percussion TBI in rats
-
-
?
N-acetyl-alpha-L-aspartyl-L-glutamate + H2O
N-acetyl-alpha-L-aspartate + L-glutamate
-
supply of the primary excitatory neurotransmitter glutamate
-
-
?
N-acetyl-alpha-L-aspartyl-L-glutamate + H2O
N-acetyl-alpha-L-aspartate + L-glutamate
-
the enzyme is involved in glutamate-mediated neurodegenerative disorders, enzyme inhibition is a mechanism for reduction of excitotoxic glutamate
-
-
?
N-acetyl-alpha-L-aspartyl-L-glutamate + H2O
N-acetyl-alpha-L-aspartate + L-glutamate
-
i.e. NAAG
-
-
?
N-acetyl-Asp-Glu + H2O
N-acetyl-Asp + Glu
-
-
-
-
?
N-acetyl-Asp-Glu + H2O
N-acetyl-Asp + Glu
-
-
-
-
?
N-acetyl-Asp-Glu + H2O
N-acetyl-Asp + Glu
-
the enzyme converts N-acetylaspartylglutamate from a neuroprotectant to a neurotoxin
-
-
?
N-Acetyl-L-Asp-L-Glu + H2O
?
-
functions as a cell surface peptidase, possibly hydrolzing peptides in prostatic fluid
-
-
?
N-Acetyl-L-Asp-L-Glu + H2O
?
-
may play a role in signaling between non-myelinating Schwann cells and peripheral axons
-
-
?
N-Acetyl-L-Asp-L-Glu + H2O
?
-
role in synaptic peptide degradation
-
-
?
N-Acetyl-L-Asp-L-Glu + H2O
N-Acetyl-L-Asp + L-Glu
-
-
-
-
?
N-Acetyl-L-Asp-L-Glu + H2O
N-Acetyl-L-Asp + L-Glu
-
-
-
-
?
N-Acetyl-L-Asp-L-Glu + H2O
N-Acetyl-L-Asp + L-Glu
-
-
-
?
N-Acetyl-L-Asp-L-Glu + H2O
N-Acetyl-L-Asp + L-Glu
-
-
-
?
N-Acetyl-L-Asp-L-Glu + H2O
N-Acetyl-L-Asp + L-Glu
-
-
-
-
?
N-Acetyl-L-Asp-L-Glu + H2O
N-Acetyl-L-Asp + L-Glu
-
-
-
?
N-Acetyl-L-Asp-L-Glu + H2O
N-Acetyl-L-Asp + L-Glu
-
-
no formation of acetate
?
N-acetyl-L-aspartyl-L-glutamate + H2O
L-glutamate + N-acetyl-L-aspartate
-
-
-
-
?
N-acetyl-L-aspartyl-L-glutamate + H2O
L-glutamate + N-acetyl-L-aspartate
-
NAALADase, a neuropeptidase that produces the neurotransmitter glutamate and N-acetyl-Laspartate throught hydrolysis of N-acetyl-L-aspartyl-L-glutamate
-
-
?
N-acetyl-L-aspartyl-L-glutamate + H2O
L-glutamate + N-acetyl-L-aspartate
-
-
-
-
?
N-acetyl-L-aspartyl-L-glutamate + H2O
N-acetyl-L-Asp + L-Glu
-
-
-
?
N-acetyl-L-aspartyl-L-glutamate + H2O
N-acetyl-L-Asp + L-Glu
-
-
-
-
?
N-acetyl-L-aspartyl-L-glutamate + H2O
N-acetyl-L-aspartate + L-glutamate
-
-
-
-
?
N-acetyl-L-aspartyl-L-glutamate + H2O
N-acetyl-L-aspartate + L-glutamate
-
-
-
?
N-acetyl-L-aspartyl-L-glutamate + H2O
N-acetyl-L-aspartate + L-glutamate
-
-
-
-
?
N-acetyl-L-aspartyl-L-glutamate + H2O
N-acetyl-L-aspartate + L-glutamate
-
-
-
?
N-acetyl-L-aspartyl-L-glutamate + H2O
N-acetyl-L-aspartate + L-glutamate
-
-
-
-
?
N-acetyl-L-aspartyl-L-glutamate + H2O
N-acetyl-L-aspartate + L-glutamate
-
-
-
?
N-acetyl-L-aspartyl-L-glutamate + H2O
N-acetyl-L-aspartate + L-glutamate
-
-
-
-
?
poly-gamma-glutamate folate + H2O
?
-
-
-
-
?
poly-gamma-glutamate folate + H2O
?
-
activity outside of the cell
-
-
?
poly-gamma-glutamate folate + H2O
?
-
-
-
-
?
poly-gamma-glutamate folate + H2O
?
-
activity outside of the cell
-
-
?
pteroyl-di-L-glutamate + H2O
L-Glu + pteroylglutamate
-
-
-
?
pteroyl-di-L-glutamate + H2O
L-Glu + pteroylglutamate
-
-
-
?
additional information
?
-
-
hydrolysis of peptide bonds of Asp or Glu to a Glu residue with unsubstituted alpha-carboxyl group. The amide bonds to Glu from the substituted benzoate in folate and methorexate molecules are resistant to hydrolysis
-
-
?
additional information
?
-
-
the enzyme interacts with filamin leading to internalization of PMSA into cells in the perinuclear region, overview
-
-
?
additional information
?
-
-
bifunctional enzyme performing folate hydrolase and N-acetylated alpha-linked acidic dipeptidase, NAALADase, activities
-
-
?
additional information
?
-
-
bifunctional enzyme performing folate hydrolase and N-acetylated alpha-linked acidic dipeptidase, NAALADase, activities
-
-
?
additional information
?
-
-
bifunctional enzyme performing folate hydrolase and N-acetylated alpha-linked acidic dipeptidase, NAALADase, activities
-
-
?
additional information
?
-
-
intestinal absorption of polyglutamyl folates involves cleavage of the glutamate side chain by FGCP
-
-
?
additional information
?
-
-
cross-linking of cell surface PSMA with specific antibodies activates the small GTPases RAS and RAC1 and the MAPKs p38 and ERK1/2 in prostate carcinoma LNCaP cells via NF-kappaB activation, overview. Proliferation of LNCaP cells is inducible by interleukin-6, CCL5 or by cross-linking of PSMA
-
-
?
additional information
?
-
-
PSMA is highly homologous to N-acetylated alpha-linked acidic dipeptidase, NAALADase
-
-
?
additional information
?
-
-
PSMA-targeted photodynamic therapy on cytoskeletal networks in prostate cancer cells results in rapid disruption of microtubules (alpha-/beta-tubulin), microfilaments (actin), and intermediate filaments (cytokeratin 8/18) in the cytoplasm of LNCaP cells. The collapse of cytoplasmic microtubules and the later nuclear translocation of alpha-/beta-tubulin are the most dramatic alternation, overview
-
-
?
additional information
?
-
-
the S1' pocket, the pharmacophore pocket of GCPIII, is shaped by residues Phe199, Arg200, Asn247, Glu414, Gly417, Leu418, Gly508, Tyr542, Lys689 and Tyr690. The specificity of GCPIII towards the P1' glutamate (or glutamate-like moieties) is determined by a combination of ionic and polar interactionsGCPIII substrate-binding cavity structure, overview
-
-
?
additional information
?
-
no substrate: amyloid-beta
-
-
?
additional information
?
-
-
no substrate: amyloid-beta
-
-
?
additional information
?
-
enzyme/hydroxamate complexes reveal an unprecedented binding mode in which the putative P1' glutarate occupies the spacious entrance funnel rather than the conserved glutamate-binding S1' pocket. This unique binding mode provides a mechanistic explanation for the structure-activity relationship data, most notably the lack of enantiospecificity and the tolerance for bulky/hydrophobic functions as substituents of a canonical glutarate moiety
-
-
?
additional information
?
-
-
enzyme/hydroxamate complexes reveal an unprecedented binding mode in which the putative P1' glutarate occupies the spacious entrance funnel rather than the conserved glutamate-binding S1' pocket. This unique binding mode provides a mechanistic explanation for the structure-activity relationship data, most notably the lack of enantiospecificity and the tolerance for bulky/hydrophobic functions as substituents of a canonical glutarate moiety
-
-
?
additional information
?
-
no cleavage of beta-citrylglutamate
-
-
?
additional information
?
-
-
no cleavage of beta-citrylglutamate
-
-
?
additional information
?
-
-
the enzyme interacts with filamin leading to internalization of PMSA into cells in the perinuclear region, overview
-
-
?
additional information
?
-
-
bifunctional enzyme performing folate hydrolase and N-acetylated alpha-linked acidic dipeptidase, NAALADase, activities
-
-
?
additional information
?
-
mouse glutamate carboxypeptidase II possesses lower catalytic efficiency but similar substrate specificity compared with the human protein
-
-
?
additional information
?
-
-
mouse glutamate carboxypeptidase II possesses lower catalytic efficiency but similar substrate specificity compared with the human protein
-
-
?
additional information
?
-
-
enzyme inhibition depresses mossy fiber-CA3 synaptic transmission
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
folyl-poly-gamma-glutamate + H2O
?
-
cleavage of the C-terminal glutamate
-
-
?
N-acetyl-alpha L-aspartyl-L-glutamate + H2O
N-acetyl-L-aspartate + L-glutamate
-
-
-
-
?
N-acetyl-alpha-L-aspartyl-L-glutamate + H2O
N-acetyl-alpha-L-aspartate + L-glutamate
N-acetyl-Asp-Glu + H2O
N-acetyl-Asp + Glu
N-Acetyl-L-Asp-L-Glu + H2O
?
N-acetyl-L-aspartyl-L-glutamate + H2O
L-glutamate + N-acetyl-L-aspartate
N-acetyl-L-aspartyl-L-glutamate + H2O
N-acetyl-L-aspartate + L-glutamate
poly-gamma-glutamate folate + H2O
?
additional information
?
-
N-acetyl-alpha-L-aspartyl-L-glutamate + H2O
N-acetyl-alpha-L-aspartate + L-glutamate
-
-
-
-
?
N-acetyl-alpha-L-aspartyl-L-glutamate + H2O
N-acetyl-alpha-L-aspartate + L-glutamate
-
-
-
-
?
N-acetyl-alpha-L-aspartyl-L-glutamate + H2O
N-acetyl-alpha-L-aspartate + L-glutamate
-
-
-
?
N-acetyl-alpha-L-aspartyl-L-glutamate + H2O
N-acetyl-alpha-L-aspartate + L-glutamate
-
i.e. NAAG, a neurodipeptide, the enzyme acts as membrane-bound receptor being recycled through clathrin coated pits, expression regulation within cells and involvement in prostate cancer and metastasis, overview
-
-
?
N-acetyl-alpha-L-aspartyl-L-glutamate + H2O
N-acetyl-alpha-L-aspartate + L-glutamate
-
supply of the primary excitatory neurotransmitter glutamate, the enzyme is involved in neurological disorders, and neuropathic and inflammatory pain
-
-
?
N-acetyl-alpha-L-aspartyl-L-glutamate + H2O
N-acetyl-alpha-L-aspartate + L-glutamate
-
the enzyme is involved in glutamate-mediated neurodegenerative disorders, enzyme inhibition is a mechanism for reduction of excitotoxic glutamate
-
-
?
N-acetyl-alpha-L-aspartyl-L-glutamate + H2O
N-acetyl-alpha-L-aspartate + L-glutamate
-
the enzyme is involved in suppressing prostate cancer invasiveness
-
-
?
N-acetyl-alpha-L-aspartyl-L-glutamate + H2O
N-acetyl-alpha-L-aspartate + L-glutamate
-
the enzyme is responsible for cleavage of NAAG to yield free glutamate
-
-
?
N-acetyl-alpha-L-aspartyl-L-glutamate + H2O
N-acetyl-alpha-L-aspartate + L-glutamate
the essential enzyme is involved in prostate cancer, stroke, amyotrophic lateral sclerosis, and neuropathic pain
-
-
?
N-acetyl-alpha-L-aspartyl-L-glutamate + H2O
N-acetyl-alpha-L-aspartate + L-glutamate
-
-
-
-
?
N-acetyl-alpha-L-aspartyl-L-glutamate + H2O
N-acetyl-alpha-L-aspartate + L-glutamate
-
-
-
-
?
N-acetyl-alpha-L-aspartyl-L-glutamate + H2O
N-acetyl-alpha-L-aspartate + L-glutamate
-
-
-
-
?
N-acetyl-alpha-L-aspartyl-L-glutamate + H2O
N-acetyl-alpha-L-aspartate + L-glutamate
-
i.e. NAAG, a neurodipeptide, the enzyme acts as membrane-bound receptor being recycled through clathrin coated pits, expression regulation within cells in prostate cancer and metastasis, overview
-
-
?
N-acetyl-alpha-L-aspartyl-L-glutamate + H2O
N-acetyl-alpha-L-aspartate + L-glutamate
the enzyme inactivates the neurotransmitter in the synaptic cleft
-
-
?
N-acetyl-alpha-L-aspartyl-L-glutamate + H2O
N-acetyl-alpha-L-aspartate + L-glutamate
-
the enzyme is responsible for glutamate supply, enzyme inhibition decreases the glutamate and increases the N-acetyl-alpha-L-aspartyl-L-glutamate concentration in the brain, which can be a method to treat opioid tolerance and diminish effects of morphine withdrawal, overview
-
-
?
N-acetyl-alpha-L-aspartyl-L-glutamate + H2O
N-acetyl-alpha-L-aspartate + L-glutamate
-
the enzyme is responsible for glutamate supply, enzyme inhibition decreases the glutamate and increases the N-acetyl-alpha-L-aspartyl-L-glutamate concentration in the brain, which can be a method to treat opioid tolerance and diminish effects of morphine withdrawal, overview
-
-
?
N-acetyl-alpha-L-aspartyl-L-glutamate + H2O
N-acetyl-alpha-L-aspartate + L-glutamate
-
enzyme regulation is mediated by glial glutamate and acetylcholine receptors in the nervous tissue
-
-
?
N-acetyl-alpha-L-aspartyl-L-glutamate + H2O
N-acetyl-alpha-L-aspartate + L-glutamate
-
-
-
-
?
N-acetyl-alpha-L-aspartyl-L-glutamate + H2O
N-acetyl-alpha-L-aspartate + L-glutamate
-
enzyme inhibition reduces acute neuronal degeneration and astrocyte damage following lateral fluid percussion traumatic brain injury
-
-
?
N-acetyl-alpha-L-aspartyl-L-glutamate + H2O
N-acetyl-alpha-L-aspartate + L-glutamate
-
i.e. NAAG, a neurodipeptide, the enzyme acts as membrane-bound receptor being recycled through clathrin coated pits, expression regulation within cells in prostate cancer and metastasis, overview
-
-
?
N-acetyl-alpha-L-aspartyl-L-glutamate + H2O
N-acetyl-alpha-L-aspartate + L-glutamate
-
i.e. NAAG, a presynaptically active endogenous neuropeptide which is cleaved by the enzyme in the extracellular space
-
-
?
N-acetyl-alpha-L-aspartyl-L-glutamate + H2O
N-acetyl-alpha-L-aspartate + L-glutamate
-
NAAG peptidase inhibitor reduces acute neuronal degeneration and astrocyte damage following lateral fluid percussion TBI in rats
-
-
?
N-acetyl-alpha-L-aspartyl-L-glutamate + H2O
N-acetyl-alpha-L-aspartate + L-glutamate
-
supply of the primary excitatory neurotransmitter glutamate
-
-
?
N-acetyl-alpha-L-aspartyl-L-glutamate + H2O
N-acetyl-alpha-L-aspartate + L-glutamate
-
the enzyme is involved in glutamate-mediated neurodegenerative disorders, enzyme inhibition is a mechanism for reduction of excitotoxic glutamate
-
-
?
N-acetyl-Asp-Glu + H2O
N-acetyl-Asp + Glu
-
-
-
-
?
N-acetyl-Asp-Glu + H2O
N-acetyl-Asp + Glu
-
-
-
-
?
N-acetyl-Asp-Glu + H2O
N-acetyl-Asp + Glu
-
the enzyme converts N-acetylaspartylglutamate from a neuroprotectant to a neurotoxin
-
-
?
N-Acetyl-L-Asp-L-Glu + H2O
?
-
functions as a cell surface peptidase, possibly hydrolzing peptides in prostatic fluid
-
-
?
N-Acetyl-L-Asp-L-Glu + H2O
?
-
may play a role in signaling between non-myelinating Schwann cells and peripheral axons
-
-
?
N-Acetyl-L-Asp-L-Glu + H2O
?
-
role in synaptic peptide degradation
-
-
?
N-acetyl-L-aspartyl-L-glutamate + H2O
L-glutamate + N-acetyl-L-aspartate
-
-
-
-
?
N-acetyl-L-aspartyl-L-glutamate + H2O
L-glutamate + N-acetyl-L-aspartate
-
NAALADase, a neuropeptidase that produces the neurotransmitter glutamate and N-acetyl-Laspartate throught hydrolysis of N-acetyl-L-aspartyl-L-glutamate
-
-
?
N-acetyl-L-aspartyl-L-glutamate + H2O
L-glutamate + N-acetyl-L-aspartate
-
-
-
-
?
N-acetyl-L-aspartyl-L-glutamate + H2O
N-acetyl-L-aspartate + L-glutamate
-
-
-
-
?
N-acetyl-L-aspartyl-L-glutamate + H2O
N-acetyl-L-aspartate + L-glutamate
-
-
-
?
N-acetyl-L-aspartyl-L-glutamate + H2O
N-acetyl-L-aspartate + L-glutamate
-
-
-
-
?
N-acetyl-L-aspartyl-L-glutamate + H2O
N-acetyl-L-aspartate + L-glutamate
-
-
-
-
?
poly-gamma-glutamate folate + H2O
?
-
activity outside of the cell
-
-
?
poly-gamma-glutamate folate + H2O
?
-
activity outside of the cell
-
-
?
additional information
?
-
-
the enzyme interacts with filamin leading to internalization of PMSA into cells in the perinuclear region, overview
-
-
?
additional information
?
-
-
intestinal absorption of polyglutamyl folates involves cleavage of the glutamate side chain by FGCP
-
-
?
additional information
?
-
-
cross-linking of cell surface PSMA with specific antibodies activates the small GTPases RAS and RAC1 and the MAPKs p38 and ERK1/2 in prostate carcinoma LNCaP cells via NF-kappaB activation, overview. Proliferation of LNCaP cells is inducible by interleukin-6, CCL5 or by cross-linking of PSMA
-
-
?
additional information
?
-
-
PSMA is highly homologous to N-acetylated alpha-linked acidic dipeptidase, NAALADase
-
-
?
additional information
?
-
-
PSMA-targeted photodynamic therapy on cytoskeletal networks in prostate cancer cells results in rapid disruption of microtubules (alpha-/beta-tubulin), microfilaments (actin), and intermediate filaments (cytokeratin 8/18) in the cytoplasm of LNCaP cells. The collapse of cytoplasmic microtubules and the later nuclear translocation of alpha-/beta-tubulin are the most dramatic alternation, overview
-
-
?
additional information
?
-
-
the enzyme interacts with filamin leading to internalization of PMSA into cells in the perinuclear region, overview
-
-
?
additional information
?
-
-
enzyme inhibition depresses mossy fiber-CA3 synaptic transmission
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(2S)-2-([hydroxy[2-(4-hydroxyphenyl)ethoxy]phosphoryl]methyl)pentanedioic acid
-
-
(2S)-2-([[2-(4-fluorophenyl)ethoxy](hydroxy)phosphoryl]methyl)pentanedioic acid
-
-
(2S)-2-([[2-(4-[[N-(tert-butoxycarbonyl)glycyl]amino]phenyl)ethoxy](hydroxy)phosphoryl]methyl)pentanedioic acid
-
-
(2S)-2-amino-3-(3,5-dioxo-1,2,4-oxadiazolidin-2-yl)propanoic acid
(2S)-2-[([[(1S)-1,3-dicarboxypropyl]amino]carbonyl)amino]pentanedioic acid
-
-
(2S)-2-[([[(1S)-1-carboxy-2-(4-hydroxyphenyl)ethyl]amino]carbonyl)amino]pentanedioic acid
-
the inhibitor has the ability to reduce the perception of inflammatory pain
(2S)-2-[([[(1S)-1-carboxy-2-phenylethyl]amino]carbonyl)amino]pentanedioic acid
-
-
(2S)-2-[([[(1S)-1-carboxy-3-(1H-tetrazol-5-yl)propyl]amino]carbonyl)amino]pentanedioic acid
-
-
(2S)-2-[([[(1S)-1-carboxy-3-(2H-tetrazol-5-yl)propyl]amino]carbonyl)amino]-4-(2H-tetrazol-5-yl)butanoic acid
-
-
(2S)-2-[([[(1S)-3-carboxy-1-(2H-tetrazol-5-yl)propyl]amino]carbonyl)amino]pentanedioic acid
-
-
(2S)-2-[([[(S)-carboxy(4-hydroxyphenyl)methyl]amino]carbonyl)amino]pentanedioic acid
-
-
(2S)-2-[[(2-[4-[(tert-butoxycarbonyl)amino]phenyl]ethoxy)(hydroxy)phosphoryl]methyl]pentanedioic acid
-
-
(2S)-2-[[([(1S)-1-carboxy-3-[1-(2-cyanoethyl)-1H-tetrazol-5-yl]propyl]amino)carbonyl]amino]pentanedioic acid
-
-
(2S)-2-[[([(1S)-3-carboxy-1-[2-(2-cyanoethyl)-2H-tetrazol-5-yl]propyl]amino)carbonyl]amino]pentanedioic acid
-
-
(2S)-2-[[butyl(hydroxy)phosphorothioyl]amino]pentanedioic acid
-
-
(2S)-2-[[ethyl(hydroxy)phosphorothioyl]amino]pentanedioic acid
-
-
(2S)-2-[[hydroxy(2-phenylethoxy)phosphoryl]methyl]pentanedioic acid
-
-
(2S)-2-[[hydroxy(3-phenylpropoxy)phosphoryl]methyl]pentanedioic acid
-
-
(2S)-2-[[hydroxy(methyl)phosphorothioyl]amino]pentanedioic acid
-
-
(2S)-2-[[hydroxy(phenyl)phosphorothioyl]amino]pentanedioic acid
-
-
(2S)-2-[[hydroxy(phenyl)phosphorothioyl]oxy]pentanedioic acid
-
-
(2S)-2-[[hydroxy(phenyl)phosphoryl]amino]pentanedioic acid
-
-
(2S)-2-[[[2-[4-(acetylamino)phenyl]ethoxy](hydroxy)phosphoryl]methyl]pentanedioic acid
-
-
(2S,2'S,4R)-4-benzyl-N,N'-carbonyldiglutamic acid
-
-
(2S,2'S,4R,4'R)-4,4'-dibenzyl-N,N'-carbonyldiglutamic acid
-
-
(2S,2'S,4R,4'R)-N,N'-carbonyl-4,4'-dimethyldiglutamic acid
-
-
(2S,2'S,4S)-N,N'-carbonyl-4-methyldiglutamic acid
-
-
(2S,2'S,4S,4'S)-N,N'-carbonyl-4,4'-dimethyldiglutamic acid
-
-
(2S,3'S)-[[(3'-amino-3'-carboxy-propyl)-hydroxyphosphinoyl]methyl]-pentanedioic acid
-
EPE, a phosphapeptide transition state analog of glutamyl-glutamate
(2S,4R)-2-[([[(1S,3R)-1,3-dicarboxybutyl]amino]carbonyl)amino]-4-methylpentanedioic acid
-
-
(2S,4S)-2-[([[(1S,3S)-1,3-dicarboxybutyl]amino]carbonyl)amino]-4-methylpentanedioic acid
-
-
(4S)-4-[([[(1S)-3-carboxy-1-(2H-tetrazol-5-yl)propyl]amino]carbonyl)amino]-4-(2H-tetrazol-5-yl)butanoic acid
-
-
(9S,13S)-1-(3-iodophenyl)-3,11-dioxo-2,4,10,12-tetraazapentadecane-9,13,15-tricarboxylic acid
-
-
(R)-2-(3-mercaptopropyl)-pentanedioic acid
(R)-2-(hydroxypentafluorophenylmethyl-phosphinoylmethyl)pentanedioic acid
(R)-2-(phosphonomethyl)-pentanedioic acid
(S)-2-(3-((R)-1-carboxy-(2-methylthio)ethyl)ureido)pentanedioic acid
DCMC
(S)-2-(3-((R)-1-carboxy-2-(4-fluorobenzylthio)ethyl)ureido)pentanedioic acid
DCFBC
(S)-2-(3-((S)-1-carboxy-(4-iodobenzamido)pentyl)ureido)pentanedioic acid
(S)-2-(3-((S)-1-carboxy-2-(4-hydroxy-3-iodophenyl)ethyl)ureido)pentanedioic acid
(S)-2-(3-((S)-1-carboxy-5-(1,2-dicarba-closo-dodecarboranylamido) pentyl)ureido)pentanedioic acid
-
(S)-2-(3-((S)-1-carboxy-5-(2-chlorobenzylamino)pentyl)ureido)pentanedioic acid
-
-
(S)-2-(3-((S)-1-carboxy-5-(2-iodobenzylamino)pentyl)ureido)-pentanedioic acid
-
-
(S)-2-(3-((S)-1-carboxy-5-(3-(4-bromophenyl)ureido)pentyl)ureido)pentanedioic acid
-
-
(S)-2-(3-((S)-1-carboxy-5-(3-(4-chlorophenyl)ureido)pentyl)ureido)pentanedioic acid
-
-
(S)-2-(3-((S)-1-carboxy-5-(3-(4-fluorophenyl)ureido)pentyl)ureido)pentanedioic acid
-
-
(S)-2-(3-((S)-1-carboxy-5-(3-(4-iodophenyl)ureido)pentyl)ureido)pentanedioic acid
(S)-2-(3-((S)-1-carboxy-5-(3-chlorobenzylamino)pentyl)ureido)pentanedioic acid
-
-
(S)-2-(3-((S)-1-carboxy-5-(3-iodobenzylamino)pentyl)ureido)-pentanedioic acid
-
-
(S)-2-(3-((S)-1-carboxy-5-(3-phenylureido)pentyl)ureido)pentanedioic acid
-
-
(S)-2-(3-((S)-1-carboxy-5-(4-bromobenzylamino)pentyl)ureido)pentanedioic acid
-
-
(S)-2-(3-((S)-1-carboxy-5-(4-chlorobenzylamino)pentyl)ureido)pentanedioic acid
-
-
(S)-2-(3-((S)-1-carboxy-5-(4-fluorobenzylamino)pentyl)ureido)pentanedioic acid
-
-
(S)-2-(3-((S)-1-carboxy-5-(4-iodobenzylamino)pentyl)ureido)-pentanedioic acid
-
-
(S)-2-(3-((S)-1-carboxy-5-(4-iodobenzylamino)pentyl)ureido)pentanedioic acid
-
i.e. MIP-1072, the compound shows affinity to and uptake into prostate cancer cells, binding analysis, overview
(S)-2-(3-((S)-1-carboxy-5-(4-iodophenylsulfonamido)pentyl)-ureido)pentanedioic acid
-
-
(S)-2-(3-((S)-1-carboxy-5-(naphthalen-1-ylmethylamino)pentyl)-ureido)pentanedioic acid
-
-
(S)-2-(3-((S)-5-(6-(4-(4-(4-acetylpiperazin-1-yl)phenyl)piperazin-1-yl)-N-(4-bromobenzyl)nicotinamido)-1-carboxypentyl)ureido)-pentanedioic acid
4200fold selectivity compared to glutamate carboxypeptidase III
(S)-2-(3-((S)-5-(6-(4-(4-(4-acetylpiperazin-1-yl)phenyl)piperazin-1-yl)nicotinamido)-1-carboxypentyl)ureido)pentanedioic acid
1400fold selectivity compared to glutamate carboxypeptidase III
(S)-2-(3-((S)-5-(benzylamino)-1-carboxypentyl)ureido)pentanedioic acid
-
-
(S)-2-(3-((S)-5-(N-(4-bromobenzyl)-6-(4-(4-(4-(4-carboxy-3-(6-hydroxy-3-oxo-3H-xanthen-9-yl)benzoyl)piperazin-1-yl)phenyl)-piperazin-1-yl)nicotinamido)-1-carboxypentyl)ureido)pentanedioic acid
1900fold selectivity compared to glutamate carboxypeptidase III
(S)-2-(3-((S)-5-(N-(4-bromobenzyl)-6-(4-(4-(4-(41-oxo-45-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)-4,7,10,13,16,19,22,25,28,31,34,37-dodecaoxa-40-azapentatetracontan-1-oyl)piperazin-1-yl)phenyl)piperazin-1-yl)nicotinamido)-1-carboxypentyl)ureido)pentanedioic acid
6600fold selectivity compared to glutamate carboxypeptidase III
(S)-2-(3-((S)-5-amino-1-carboxypentyl)ureido)pentanedioic acid
-
-
(S)-2-(3-(4-iodobenzyl)ureido)pentanedioic acid
-
-
(S)-2-(3-mercaptopropyl)-pentanedioic acid
(S)-2-(hydroxypentafluorophenylmethyl-phosphinoylmethyl)pentanedioic acid
(S)-2-(phosphonomethyl)-pentanedioic acid
(S)-2-[3-((S)-1-carboxy-2-(4-hydroxyphenyl)ethyl)ureido]pentanedioic acid
(S)-2-[3-((S)-1-carboxy-2-phenylethyl)ureido]pentanedioic acid
-
-
(S)-2-[3-((S)-1-carboxy-3-(1H-tetrazol-5-yl)propyl)ureido]pentanedioic acid
(S)-2-[3-((S)-1-carboxy-3-(methylsulfanyl)propyl)ureido]pentanedioic acid
(S)-2-[3-((S)-1-carboxy-3-methylbutyl)ureido]pentanedioic acid
(S)-2-[3-((S)-1-carboxy-3-[1-(2-cyanoethyl)-1H-tetrazol-5-yl]propyl)ureido]pentanedioic acid
-
-
(S)-2-[3-((S)-3-carboxy-1-(1H-tetrazol-5-yl)propyl)ureido]pentanedioic acid
-
-
(S)-2-[3-((S)-3-carboxy-1-[1-(2-cyanoethyl)-1H-tetrazol-5-yl]propyl)ureido]pentanedioic acid
-
-
(S)-2-[3-((S)-alpha-carboxy-4-hydroxybenzyl)ureido]pentanedioic acid
-
-
(S)-2-[3-((S)-alpha-carboxybenzyl)ureido]pentanedioic acid
-
-
(S)-2-[3-(S)-(1,3-dicarboxypropyl)ureido]pentanedioinc acid
(S)-alpha-ethylglutamate
-
specific group II metabotropic glutamate receptor antagonist, in vivo activity
(S,S)-4,4'-bis[1-(2-cyanoethyl)-1H-tetrazol-5-yl]-2,2'-ureylenedibutyric acid
-
-
(S,S)-4,4'-bis[1-(2-cyanoethyl)-1H-tetrazol-5-yl]-4,4'-ureylenedibutyric acid
-
-
(S,S)-4,4'-di-(1H-tetrazol-5-yl)-2,2'-ureylenedibutyric acid
-
-
(S,S)-4,4'-di-(1H-tetrazol-5-yl)-4,4'-ureylenedibutyric acid
-
-
(S,S)-N,N'-carbonyl-2,2'-dimethyldiglutamic acid
-
-
(t-Bu)Cys-PSI[C-O]-Glu
-
IC50: 29 nM
(Z)-N-(N-Acetyldehydroaspartyl)-L-Glu
-
-
1,10-phenanthroline
-
1 mM, 90% inhibition
2-(2-carboxy-5-mercaptopentyl)benzoic acid
-
IC50: 1700 nM
2-(3-carbamoylbenzyl)-5-mercaptopentanoic acid
-
IC50: 2200 nM
2-(3-carboxybenyl)succinic acid
-
IC50: 0.015 mM
2-(3-cyanobenzyl)-5-mercaptopentanoic acid
-
IC50: 1800 nM
2-(3-hydroxybenzyl)-3-phosphonopropanoic acid
-
IC50: 508 nM
2-(3-mercaptopropyl)-pentanedioic acid
2-(3-mercaptopropyl)pentanedioic acid
2-(3-sulfanylpropyl)pentanedioic acid
-
i.e. GPI-5693, attenuates cocaine-induced conditioned place preference
2-(phosphonomethyl) pentanedioic acid
inhibitor completely blocks N-acetylaspartylglutamate cleavage activity but not Amyloid-beta degradation
2-(phosphonomethyl)-4-(5H-tetrazol-5-yl)butanoic acid
-
IC50: 175 nM
2-(phosphonomethyl)-pentanedioic acid
2-(phosphonomethyl)hexanedioic acid
-
IC50: 185 nM
2-(phosphonomethyl)hexanoic acid
-
IC50: 185 nM
2-(phosphonomethyl)pentandioic acid
10fold selectivity compared to glutamate carboxypeptidase III
2-(phosphonomethyl)pentanedioic acid
2-(Phosphonomethyl)pentanoate
-
-
2-(phosphonomethyl)succinic acid
-
IC50: 2200 nM
2-([hydroxy[3-(trifluoromethyl)benzyl]phosphoryl]methyl)pentanedioic acid
-
IC50: 55 nM
2-([hydroxy[hydroxy(phenyl)methyl]phosphoryl]methyl)pentanedioic acid
-
IC50: 55 nM
2-([hydroxy[hydroxy(pyridin-4-yl)methyl]phosphoryl]methyl)pentanedioic acid
-
IC50: 10 nM
2-amino-3-(3,5-dioxo[1,2,4]oxadiazolidin-2-yl)propionic acid
-
i.e. quisqualic acid, a glutamate-like inhibitor of GCPIII and GCPII
2-benzyl-3-phosphonopropanoic acid
-
IC50: 548 nM
2-benzyl-5-mercaptopentanoic acid
-
IC50: 1400 nM
2-oxoglutarate
-
0.1 mM, 46% inhibition
2-phosphonomethyl-pentanedoic acid
-
2-PMPA
2-[(hydroxy[[(4-methoxyphenyl)amino]methyl]phosphoryl)methyl]pentanedioic acid
-
IC50: 3 nM
2-[[(2,4-dicarboxybutyl)(hydroxy)phosphoryl]methyl]pentanedioic acid
-
IC50: 0.5 nM
2-[[(2-carboxy-3-phenylpropyl)(hydroxy)phosphoryl]methyl]pentanedioic acid
-
IC50: 2 nM
2-[[(2-carboxy-4-phenylbutyl)(hydroxy)phosphoryl]methyl]pentanedioic acid
-
IC50: 2 nM
2-[[(2-carboxyethyl)(hydroxy)phosphoryl]methyl]pentanedioic acid
-
IC50: 1 nM
2-[[(2-carboxypropyl)(hydroxy)phosphoryl]methyl]pentanedioic acid
-
IC50: 1.5 nM
2-[[(2-fluorobenzyl)(hydroxy)phosphoryl]methyl]pentanedioic acid
-
IC50: 156 nM
2-[[(3,5-difluorobenzyl)(hydroxy)phosphoryl]methyl]pentanedioic acid
-
IC50: 49 nM
2-[[(3-aminobenzyl)(hydroxy)phosphoryl]methyl]pentanedioic acid
-
IC50: 143 nM
2-[[(3-fluorobenzyl)(hydroxy)phosphoryl]methyl]pentanedioic acid
-
IC50: 70 nM
2-[[(4-fluorobenzyl)(hydroxy)phosphoryl]methyl]pentanedioic acid
-
IC50: 64 nM
2-[[(anilinomethyl)(hydroxy)phosphoryl]methyl]pentanedioic acid
-
IC50: 4 nM
2-[[benzyl(hydroxy)phosphoryl]methyl]pentanedioic acid
2-[[hydroxy(2-phenylethyl)phosphoryl]methyl]pentanedioic acid
2-[[hydroxy(3-nitrobenzyl)phosphoryl]methyl]pentanedioic acid
-
IC50 59 nM
2-[[hydroxy(3-phenylpropyl)phosphoryl]methyl]pentanedioic acid
-
IC50: 230 nM
2-[[hydroxy(4-methoxybenzyl)phosphoryl]methyl]pentanedioic acid
-
IC50: 90 nM
2-[[hydroxy(4-methylbenzyl)phosphoryl]methyl]pentanedioic acid
-
IC50: 68 nM
2-[[hydroxy(pentafluorobenzyl)phosphoryl]methyl]pentanedioic acid
-
IC50: 82 nM. Significantly prevents neurodegeneration in a middle cerebral artery occlusion model of cerebral ischemia. In the chronic constrictive model of neuropathic pain, the inhibitor sifnificantly attenuats the hypersensitivity observed with saline-treated animals
2-[[hydroxy(phenyl)phosphoryl]methyl]pentanedioic acid
-
IC50: 2930 nM
2-[[hydroxy(propyl)phosphoryl]methyl]pentanedioic acid
2-[[[(3-fluorophenyl)(hydroxy)methyl](hydroxy)phosphoryl]methyl]pentanedioic acid
-
IC50: 16 nM
2-[[[(benzylamino)methyl](hydroxy)phosphoryl]methyl]pentanedioic acid
-
IC50: 59 nM
2-[[[3,5-bis(trifluoromethyl)benzyl](hydroxy)phosphoryl]methyl]pentanedioic acid
-
IC50: 55 nM
2-[[[3-(benzyloxy)-2-methyl-3-oxopropyl](hydroxy)phosphoryl]methyl]pentanedioic acid
-
IC50: 95 nM
2-{[2-Carboxy-3-(4-methoxy-phenylamino)-propyl]-hydroxy-phosphinoylmethyl}-pentanedioic acid
-
IC50: 3 nM
3-(1-carboxy-4-mercaptobutoxy)benzoic acid
-
IC50: 14 nM
3-(2-carbamoyl-5-mercaptopentyl)benzoic acid
-
IC50: 640 nM
3-(2-carboxy-3-hydroxycarbamoylpropyl)benzoic acid
-
IC50: 0.015 mM
3-(2-carboxy-3-phosphonopropyl)benzoic acid
-
IC50: 120 nM
3-(2-carboxy-5-mercaptopentyl)benzoic acid
-
IC50: 15 nM
3-(2-carboxy-5-mercaptopentyl)benzoic acid methyl ester
-
IC50: 2700 nM
3-(2-carboxy-5-mercaptosulfanylpentyl)benzoic acid
-
IC50: 0.02 mM
3-(2-carboxy-5-tritylsulfanylpentyl)benzoic acid
-
IC50: 0.02 mM
3-(2-oxotetrahydro-thiopyran-3-yl)propionic acid
-
prodrug of inhibitor 2-(3-mercaptopropyl)pentanedioic acid
3-(3-mercaptopropyl)pentanedioic acid
-
presynaptic action of enzyme inhibition, enzyme inhibition depresses mossy fiber-CA3 synaptic transmission
3-(5-mercapto-2-methoxycarbonylpentyl)benzoic acid
-
IC50: 730 nM
3-[(1-carboxy-4-mercaptobutyl)thio]benzoic acid
-
IC50: 32 nM
3-[2-carboxy-3-(hydroxypentafluorophenylmethylphosphinoyl)propyl]benzoic acid
-
IC50: 2400 nM
4,4'-phosphinicobis(butane-1,3-dicarboxylic acid)
4-(2-carboxy-5-mercaptopentyl)benzoic acid
-
IC50: 63 nM
4-(3-hydroxyphenyl)-2-(phosphonomethyl)butanoic acid
-
IC50: 508 nM
4-cyano-2-(phosphonomethyl)butanoic acid
-
IC50: 335 nM
4-phenyl-2-(phosphonomethyl)butanoic acid
-
IC50: 199 nM
4-[(2-(R))-2-carboxy-5-(oxidanylamino)-5-oxidanylidene-pentyl]benzoic acid
-
4-[(2-(S))-2-carboxy-5-(oxidanylamino)-5-oxidanylidene-pentyl]benzoic acid
-
4-[[bis[[(isopropoxycarbonyl)oxy]methoxy]phosphoryl]-methyl]-5-[[(isopropoxycarbonyl)oxy]methoxy]-5-oxopentanoic acid
5-oxoheptane-1,3,7-tricarboxylic acid
-
0.1 mM, 35% inhibition
5-oxononane-1,3,7,9-tetracarboxylic acid
-
inhibitor possesses mGluR3 agonist activity
Ala-Glu
-
0.0061 mM, 50% inhibition
Asp-Ala
-
0.1 mM, 26% inhibition
Asp-Asp
-
0.1 mM, 42% inhibition
Asp-Phe
-
0.1 mM, 22% inhibition
Asp-PSI[C-O-S]-Glu
-
IC50: 0.0461 mM
Asp-PSI[C-O]-Asp
-
IC50: 0.0038 mM
Asp-PSI[S]-Asp
-
0.1 mM, 42% inhibition
aspartate
-
0.1 mM, 42% inhibition
bestatin
-
0.29 mM, 79% inhibition
Cys-PSI[C-O-S]-Glu
-
IC50: 6.9 nM
cysteate
-
0.1 mM, 40% inhibition
cysteine sulfinate
-
0.1 mM, 42% inhibition
D-Glu-D-Glu
-
0.1 mM, 50% inhibition
D-Glu-PSI[C-O]-D-Glu
-
0.1 mM, 67% inhibition
D-Glu-PSI[C-O]-Glu
-
0.001 mM, 25% inhibition
diphenyl 2-[[[2-[4-([[7-(diethylamino)-2-oxo-2H-chromen-3-yl]carbamoyl]amino)phenyl]ethoxy](hydroxy)phosphoryl]methyl]pentanedioate
-
-
dithiothreitol
-
1 mM, 94.8% inhibition
DKFZ-PSMA-11
720fold selectivity compared to glutamate carboxypeptidase III
DUPA
-
enzyme active site binding structure, docking and modelling, detailed overview
Glu-Asp
-
0.1 mM, 27% inhibition
Glu-PSI[C-O-C-O]-Glu
-
0.001 mM, 9% inhibition
Glu-PSI[C-O]-Glu
-
IC50: 47 nM
glutathione
-
i.e. gamma-Glu-Cys-Gly, 0.019 mM, 50% inhibition
Gly-Gly-Glu
-
0.00098 mM, 50% inhibition
Gly-PSI[C-O-S]-Glu
-
0.001 mM, 46% inhibition
GPI 5693
-
i.e. (R,S)-2-(3-mercaptopropyl)-pentanedioic acid or 2-MPPA, pharmacokinetics and safety of the NAALADase-inhibitor and its effects on the central nervous system after application in vivo, overview
GPI-16476
-
enantiomer of GPI-5693
GPI-16477
-
enantiomer of GPI-5693
GPI-18431
-
enzyme active site binding structure, docking and modelling, detailed overview
Ibotenate
-
0.1 mM, 45% inhibition
iodoacetate
-
1 mM, 38% inhibition
L-2-Amino-4-phosphonobutanoate
-
0.1 mM, 37% inhibition
N-(3,4-Dicarboxybutanoyl)glutamic acid
-
-
N-(4-fluorobenzoyl)-L-isoleucyl-O-[[[(1S)-1,3-dicarboxypropyl]amino](hydroxy)phosphoryl]-L-serine
-
N-(4-fluorobenzoyl)-L-valyl-O-[[[(1S)-1,3-dicarboxypropyl]amino](hydroxy)phosphoryl]-L-serine
-
N-(Dicarboxymethyl)acetylglutaminic acid
-
-
N-(tert-butoxycarbonyl)glycyl-N-[4-[2-([[(2S)-2,4-dicarboxybutyl](hydroxy)phosphoryl]oxy)ethyl]phenyl]-L-prolinamide
-
-
N-(tert-butoxycarbonyl)glycylglycyl-N-[4-[2-([[(2S)-2,4-dicarboxybutyl](hydroxy)phosphoryl]oxy)ethyl]phenyl]glycinamide
-
-
N-([(1S)-1-carboxy-5-([(4-iodophenyl)carbonyl]amino)pentyl]carbamoyl)-L-glutamic acid
P1'-diversified urea-based inhibitor, in complex with enzyme PDB entry 3D7H
N-2-([(1S)-1-carboxy-2-(furan-2-yl)ethyl]carbamoyl)-N-6-(4-iodobenzoyl)-L-lysine
P1'-diversified urea-based inhibitor, in complex with enzyme PDB entry 4OC3
N-2-([(1S)-1-carboxybut-3-yn-1-yl]carbamoyl)-N-6-(4-iodobenzoyl)-L-lysine
P1'-diversified urea-based inhibitor, in complex with enzyme PDB entry 4OC2
N-Acetyl-Asp-Gln
-
0.1 mM, 49% inhibition
N-Acetyl-Asp-Glu-Asp
-
0.1 mM, 49% inhibition
N-Acetyl-Asp-Ser-Gly
-
0.1 mM, 37% inhibition
N-Acetyl-beta-L-Asp-L-Glu
N-Acetyl-Glu-Asp
-
0.036 mM, 50% inhibition
N-Acetyl-Glu-Glu
-
0.00031 mM, 50% inhibition
N-acetyl-L-Asp
-
0.1 mM, 38% inhibition
N-Acetyl-L-Asp-L-Glu
-
0.00054 mM, 50% inhibition
N-acetyl-L-Glu
-
0.058 mM, 50% inhibition
N-[(2-benzamidoethoxy)(hydroxy)phosphoryl]-L-glutamic acid
-
N-[4-carboxy-3-(carboxymethyl)-3-hydroxybutanoyl]-L-glutamic acid
N-[hydroxy(4-phenylbutoxy)phosphoryl]-L-glutamic acid
-
N-[[(1S)-1-carboxy-2-(4-hydroxyphenyl)ethyl]carbamoyl]-L-glutamic acid
N-[[(1S)-1-carboxy-3-(methylsulfanyl)propyl]carbamoyl]-L-glutamic acid
N-[[(1S)-1-carboxy-3-methylbutyl]carbamoyl]-L-glutamic acid
N-[[(1S)-1-carboxy-5-(4-iodobenzamido)pentyl]carbamoyl]-L-glutamic acid
N-[[(1S)-1-carboxy-5-([5-[3-(3-[[[2-[[[5-(2-carboxyethyl)-2-hydroxyphenyl]methyl](carboxymethyl)amino]ethyl](carboxymethyl)amino]methyl]-4-hydroxyphenyl)propanamido]pentanoyl]amino)pentyl]carbamoyl]-L-glutamic acid
N-[[(1S)-5-([(4-bromophenyl)methyl][6-[4-(4-[4-[4-carboxy-3-(6-hydroxy-3-oxo-3H-xanthen-9-yl)benzoyl]piperazin-1-yl]phenyl)piperazin-1-yl]pyridine-3-carbony]amino)-1-carboxypentyl]carbamoyl]-L-glutamic acid
N-[[(1S)-5-acetamido-1-carboxypentyl]carbamoyl]-L-glutamic acid
N-[[(1S)-5-[acetyl[(4-bromophenyl)methyl]amino]-1-carboxypentyl]carbamoyl]-L-glutamic acid
N-[[(2R)-2-benzamido-2-carboxyethoxy](hydroxy)phosphoryl]-L-glutamic acid
-
N-[[(2S)-2-benzamido-2-carboxyethoxy](hydroxy)phosphoryl]-L-glutamic acid
-
N-[[(2S)-2-[[(6S)-6-amino-6-carboxy-3-oxohexyl]amino]-2-carboxyethoxy](hydroxy)phosphoryl]-L-glutamic acid
-
N-[[([1,1'-biphenyl]-4-yl)methoxy](hydroxy)phosphoryl]-L-glutamic acid
-
N-[[[(1S)-1-carboxy-3-methylbutyl]amino]carbonyl]-L-glutamic acid
i.e. ZJ-43. 160fold selectivity compared to glutamate carboxypeptidase III
Phe-Glu
-
0.077 mM, 50% inhibition
puromycin
-
0.5 mM, 55% inhibition
pyroglutamate
-
0.1 mM, 27% inhibition
pyropheophorbide-a conjugate
-
i.e. Ppa-2 conjugate, non-specificity of unconjugated Ppa, conjugation of a peptidomimetic inhibitor of PSMA to the porphyrinic PS, pyropheophorbide-a gives
quinolinate
-
0.1 mM, 41% inhibition
S-2-((2-(S-4-(4-18F-fluorobenzamido)-4-carboxybutanamido)-S-2-carboxyethoxy)hydroxyphosphorylamino)-pentanedioic acid
-
-
S-2-((2-(S-4-amino-4-carboxybutanamido)-S-2-carboxyethoxy)-hydroxyphosphorylamino)-pentanedioic acid
-
phosphoramidate
Serine O-sulfate
-
0.042 mM, 50% inhibition
t-BuNHC(O)-Glu
-
0.001 mM, 10% inhibition
Tyr-Glu
-
0.1 mM, 45% inhibition
Val-Glu-Glu
-
0.036 mM, 50% inhibition
ZJ-43
-
i.e. (S)-2-[3-((S)-1-carboxy-3-methylbutyl)ureido]pentanedioic acid, the inhibitor enhances extracellular NAAG levels and reduces extracellular levels of amino acids neurotransmitter following traumatic brain injury in vivo
ZJ43
-
i.e. (S)-2-[3-((S)-1-carboxy-3-methylbutyl)ureido]pentanedioic acid
[HO2C(CH2)2CH(CO2H)CH2]2P(O)(OH)
-
-
(2S)-2-amino-3-(3,5-dioxo-1,2,4-oxadiazolidin-2-yl)propanoic acid
-
(2S)-2-amino-3-(3,5-dioxo-1,2,4-oxadiazolidin-2-yl)propanoic acid
-
(R)-2-(3-mercaptopropyl)-pentanedioic acid
-
equally potent as the S-isomer, 0.000085 mM
(R)-2-(3-mercaptopropyl)-pentanedioic acid
-
antinociceptide effects in the chronic constriction injury model, cell culture model of cerebral ischemia
(R)-2-(hydroxypentafluorophenylmethyl-phosphinoylmethyl)pentanedioic acid
-
40fold less potent than the S-isomer, IC50: 0.0014 mM
(R)-2-(hydroxypentafluorophenylmethyl-phosphinoylmethyl)pentanedioic acid
-
neuroprotective effects in the middle cerebral artery occlusion model, cell culture model of cerebral ischemia
(R)-2-(phosphonomethyl)-pentanedioic acid
-
less potent than the S-isomer, IC50: 0.000030 mM
(R)-2-(phosphonomethyl)-pentanedioic acid
-
-
(S)-2-(3-((S)-1-carboxy-(4-iodobenzamido)pentyl)ureido)pentanedioic acid
DCIBzL
(S)-2-(3-((S)-1-carboxy-(4-iodobenzamido)pentyl)ureido)pentanedioic acid
830fold selectivity compared to glutamate carboxypeptidase III
(S)-2-(3-((S)-1-carboxy-2-(4-hydroxy-3-iodophenyl)ethyl)ureido)pentanedioic acid
DCIT
(S)-2-(3-((S)-1-carboxy-2-(4-hydroxy-3-iodophenyl)ethyl)ureido)pentanedioic acid
-
DCIT
(S)-2-(3-((S)-1-carboxy-5-(3-(4-iodophenyl)ureido)pentyl)ureido)pentanedioic acid
-
i.e. MIP-1095, the compound shows affinity to and uptake into prostate cancer cells, binding analysis, overview
(S)-2-(3-((S)-1-carboxy-5-(3-(4-iodophenyl)ureido)pentyl)ureido)pentanedioic acid
-
-
(S)-2-(3-mercaptopropyl)-pentanedioic acid
-
equally potent as the R-isomer, 0.000067 mM
(S)-2-(3-mercaptopropyl)-pentanedioic acid
-
antinociceptide effects in the chronic constriction injury model, cell culture model of cerebral ischemia
(S)-2-(hydroxypentafluorophenylmethyl-phosphinoylmethyl)pentanedioic acid
-
40fold more potent than the R-isomer, IC50: 0.000034 mM
(S)-2-(hydroxypentafluorophenylmethyl-phosphinoylmethyl)pentanedioic acid
-
neuroprotective effects in the middle cerebral artery occlusion model, cell culture model of cerebral ischemia
(S)-2-(phosphonomethyl)-pentanedioic acid
-
more potent than the R-isomer, IC50: 0.0000001 mM
(S)-2-(phosphonomethyl)-pentanedioic acid
-
-
(S)-2-[3-((S)-1-carboxy-2-(4-hydroxyphenyl)ethyl)ureido]pentanedioic acid
-
-
(S)-2-[3-((S)-1-carboxy-2-(4-hydroxyphenyl)ethyl)ureido]pentanedioic acid
-
i.e. inhibitor ZJ17
(S)-2-[3-((S)-1-carboxy-2-(4-hydroxyphenyl)ethyl)ureido]pentanedioic acid
-
i.e. inhibitor ZJ17
(S)-2-[3-((S)-1-carboxy-3-(1H-tetrazol-5-yl)propyl)ureido]pentanedioic acid
-
-
(S)-2-[3-((S)-1-carboxy-3-(1H-tetrazol-5-yl)propyl)ureido]pentanedioic acid
-
i.e. inhibitor ZJ38
(S)-2-[3-((S)-1-carboxy-3-(1H-tetrazol-5-yl)propyl)ureido]pentanedioic acid
-
i.e. inhibitor ZJ38
(S)-2-[3-((S)-1-carboxy-3-(methylsulfanyl)propyl)ureido]pentanedioic acid
-
i.e. inhibitor ZJ11
(S)-2-[3-((S)-1-carboxy-3-(methylsulfanyl)propyl)ureido]pentanedioic acid
-
i.e. inhibitor ZJ11
(S)-2-[3-((S)-1-carboxy-3-methylbutyl)ureido]pentanedioic acid
-
i.e. inhibitor ZJ43
(S)-2-[3-((S)-1-carboxy-3-methylbutyl)ureido]pentanedioic acid
-
i.e. inhibitor ZJ43
(S)-2-[3-(S)-(1,3-dicarboxypropyl)ureido]pentanedioinc acid
-
-
(S)-2-[3-(S)-(1,3-dicarboxypropyl)ureido]pentanedioinc acid
-
-
2-(3-mercaptopropyl)-pentanedioic acid
-
2-MPPA, specific, potent, competitive inhibition, has higher oral bioavailability compared to 2-PMPA, acts neuroprotective in vivo, e.g. in case of ischemic stroke, and provides analgesia
2-(3-mercaptopropyl)-pentanedioic acid
-
i.e. 2-MPPA, IC50: 90 nM
2-(3-mercaptopropyl)-pentanedioic acid
-
i.e. 2-MPPA or GPI5693
2-(3-mercaptopropyl)-pentanedioic acid
-
2-MPPA, prevents morphine tolerance without affecting the acute morphine antinociception in vivo
2-(3-mercaptopropyl)-pentanedioic acid
-
2-MPPA, specific, potent, competitive inhibition, acts neuroprotective in vivo, e.g. in case of ischemic stroke, and provides analgesia
2-(3-mercaptopropyl)-pentanedioic acid
-
i.e. 2-MPPA or GPI5693
2-(3-mercaptopropyl)pentanedioic acid
-
IC50: 90 nM. Orally bioavailable in rats
2-(3-mercaptopropyl)pentanedioic acid
-
orally bioavailable inhibitor
2-(3-mercaptopropyl)pentanedioic acid
-
in rat liver microsomes, 2-(3-mercaptopropyl)pentanedioic acid is gradually produced from 3-(2-oxotetrahydro-thiopyran-3-yl)propionic acid, a thiolactone derived from the compound. 2-(3-Mercaptopropyl)pentanedioic acid is detected in plasma at concentrations well above its IC50 value for GCPII following oral administration of 3-(2-oxotetrahydro-thiopyran-3-yl)propionic acid in rats
2-(phosphonomethyl)-pentanedioic acid
-
2-PMPA
2-(phosphonomethyl)-pentanedioic acid
-
2-PMPA, specific, potent, competitive inhibition, acts neuroprotective in vivo, e.g. in case of ischemic stroke, and provides analgesia
2-(phosphonomethyl)-pentanedioic acid
i.e. 2-PMPA
2-(phosphonomethyl)-pentanedioic acid
-
i.e. 2-PMPA
2-(phosphonomethyl)-pentanedioic acid
2-PMPA, GCPIII IC50: 94 nM, GCPII IC50: 6.74 nM
2-(phosphonomethyl)-pentanedioic acid
-
2-PMPA
2-(phosphonomethyl)-pentanedioic acid
-
2-PMPA, specific GCPII inhibitor, in vivo activity
2-(phosphonomethyl)-pentanedioic acid
-
-
2-(phosphonomethyl)-pentanedioic acid
-
2-PMPA, specific, potent, competitive inhibition, acts neuroprotective in vivo, e.g. in case of ischemic stroke, and provides analgesia
2-(phosphonomethyl)-pentanedioic acid
-
i.e. 2-PMPA, enzyme inhibition protects the rats in vivo against ischemic injury to the brain and spinal cord, and hypoxic and metabolic injury to neuronal cells in culture
2-(phosphonomethyl)-pentanedioic acid
-
i.e. 2-PMPA
2-(phosphonomethyl)pentanedioic acid
-
potent inhibitor, robust neuroprotective efficacy in many neurological disease models
2-(phosphonomethyl)pentanedioic acid
-
competitive
2-(phosphonomethyl)pentanedioic acid
-
-
2-(phosphonomethyl)pentanedioic acid
-
2-PMPA
2-(phosphonomethyl)pentanedioic acid
completely blocks the NAAG hydrolysis without any effect on amyloid-beta degradation
2-(phosphonomethyl)pentanedioic acid
-
2-(phosphonomethyl)pentanedioic acid
-
2-(phosphonomethyl)pentanedioic acid
potent inhibitor, robust neuroprotective efficacy in many neurological disease models
2-(phosphonomethyl)pentanedioic acid
-
IC50: 5.1 nM
2-(phosphonomethyl)pentanedioic acid
-
IC50: 0.3 nM
2-(phosphonomethyl)pentanedioic acid
-
requires long-term daily dosing
2-(phosphonomethyl)pentanedioic acid
-
i.e. 2-PMPA, inhibits cocaine-induced behavioural sensitization
2-(phosphonomethyl)pentanedioic acid
-
i.e. 2-PMPA, a N-acetylated-alpha-linkedacidic dipeptidase inhibitor, attenuates cocaine self-administration and cocaine-induced reinstatement of drug seeking of rats
2-(phosphonomethyl)pentanedioic acid
-
2-[[benzyl(hydroxy)phosphoryl]methyl]pentanedioic acid
-
IC50: 70 nM
2-[[benzyl(hydroxy)phosphoryl]methyl]pentanedioic acid
-
IC50: 53 nM
2-[[hydroxy(2-phenylethyl)phosphoryl]methyl]pentanedioic acid
-
IC50: 150 nM
2-[[hydroxy(2-phenylethyl)phosphoryl]methyl]pentanedioic acid
-
IC50: 149 nM
2-[[hydroxy(propyl)phosphoryl]methyl]pentanedioic acid
-
IC50: 560 nM
2-[[hydroxy(propyl)phosphoryl]methyl]pentanedioic acid
-
IC50: 360 nM
4,4'-phosphinicobis(butane-1,3-dicarboxylic acid)
-
i.e. PBDA, effects of stereoisomers, overview
4,4'-phosphinicobis(butane-1,3-dicarboxylic acid)
-
i.e. PBDA
4-[[bis[[(isopropoxycarbonyl)oxy]methoxy]phosphoryl]-methyl]-5-[[(isopropoxycarbonyl)oxy]methoxy]-5-oxopentanoic acid
-
the orally bioavailable prodrug affords excellent release of 2-phosphonomethylpentanedioic acid following oral administration in both mice and dog
4-[[bis[[(isopropoxycarbonyl)oxy]methoxy]phosphoryl]-methyl]-5-[[(isopropoxycarbonyl)oxy]methoxy]-5-oxopentanoic acid
the orally bioavailable prodrug affords excellent release of 2-phosphonomethylpentanedioic acid following oral administration in both mice and dog
Asp-Glu
-
0.0024 mM, 50% inhibition
diazabicycloalkane
-
cis- and trans-isomers, dipeptide mimetic
-
diazabicycloalkane
-
cis- and trans-isomers, dipeptide mimetic
-
EDTA
-
EDTA
-
1 mM, 96.3% inhibition
EGTA
-
1 mM, 92% inhibition
gamma-Glu-Glu
-
0.0095 mM, 50% inhibition
Glu-Glu
-
0.00075 mM, 50% inhibition
Glu-Glu-Glu
-
0.062 mM, 50% inhibition
Gly-Glu
-
0.008 mM, 50% inhibition
GPI5232
-
i.e. 2-([((hydroxypentyfluorophenyl)methyl)phosphinoyl]methyl)pentanedioic acid
GPI5232
-
a 2-PMPA analogue
GPI5232
-
i.e. 2-([((hydroxypentyfluorophenyl)methyl)phosphinoyl]methyl)pentanedioic acid
L-Glu
-
-
L-Glu
-
0.032 mM, 50% inhibition
N-Acetyl-beta-L-Asp-L-Glu
-
-
N-Acetyl-beta-L-Asp-L-Glu
-
-
N-[4-carboxy-3-(carboxymethyl)-3-hydroxybutanoyl]-L-glutamic acid
-
N-[4-carboxy-3-(carboxymethyl)-3-hydroxybutanoyl]-L-glutamic acid
-
N-[[(1S)-1-carboxy-2-(4-hydroxyphenyl)ethyl]carbamoyl]-L-glutamic acid
-
i.e. inhibitor ZJ17, antinociceptive effect of the inhibitor in the rat formalin test and the rat neuropathic pain model, overview
N-[[(1S)-1-carboxy-2-(4-hydroxyphenyl)ethyl]carbamoyl]-L-glutamic acid
-
i.e. inhibitor ZJ17, antinociceptive effect of the inhibitor in the rat formalin test and the rat neuropathic pain model, agonist and antagonist activity on recombinantly expressed metabotropic glutamate receptor, overview
N-[[(1S)-1-carboxy-3-(methylsulfanyl)propyl]carbamoyl]-L-glutamic acid
-
i.e. inhibitor ZJ11, antinociceptive effect of the inhibitor in the rat formalin test and the rat neuropathic pain model, overview
N-[[(1S)-1-carboxy-3-(methylsulfanyl)propyl]carbamoyl]-L-glutamic acid
-
i.e. inhibitor ZJ11, antinociceptive effect of the inhibitor in the rat formalin test and the rat neuropathic pain model, agonist and antagonist activity on recombinantly expressed metabotropic glutamate receptor, overview
N-[[(1S)-1-carboxy-3-methylbutyl]carbamoyl]-L-glutamic acid
-
i.e. inhibitor ZJ43, antinociceptive effect of the inhibitor in the rat formalin test and the rat neuropathic pain model, overview
N-[[(1S)-1-carboxy-3-methylbutyl]carbamoyl]-L-glutamic acid
-
N-[[(1S)-1-carboxy-3-methylbutyl]carbamoyl]-L-glutamic acid
-
N-[[(1S)-1-carboxy-3-methylbutyl]carbamoyl]-L-glutamic acid
-
i.e. inhibitor ZJ43, antinociceptive effect of the inhibitor in the rat formalin test and the rat neuropathic pain model, agonist and antagonist activity on recombinantly expressed metabotropic glutamate receptor, overview
N-[[(1S)-1-carboxy-5-(4-iodobenzamido)pentyl]carbamoyl]-L-glutamic acid
-
N-[[(1S)-1-carboxy-5-(4-iodobenzamido)pentyl]carbamoyl]-L-glutamic acid
-
N-[[(1S)-1-carboxy-5-([5-[3-(3-[[[2-[[[5-(2-carboxyethyl)-2-hydroxyphenyl]methyl](carboxymethyl)amino]ethyl](carboxymethyl)amino]methyl]-4-hydroxyphenyl)propanamido]pentanoyl]amino)pentyl]carbamoyl]-L-glutamic acid
-
N-[[(1S)-1-carboxy-5-([5-[3-(3-[[[2-[[[5-(2-carboxyethyl)-2-hydroxyphenyl]methyl](carboxymethyl)amino]ethyl](carboxymethyl)amino]methyl]-4-hydroxyphenyl)propanamido]pentanoyl]amino)pentyl]carbamoyl]-L-glutamic acid
-
N-[[(1S)-5-([(4-bromophenyl)methyl][6-[4-(4-[4-[4-carboxy-3-(6-hydroxy-3-oxo-3H-xanthen-9-yl)benzoyl]piperazin-1-yl]phenyl)piperazin-1-yl]pyridine-3-carbony]amino)-1-carboxypentyl]carbamoyl]-L-glutamic acid
-
N-[[(1S)-5-([(4-bromophenyl)methyl][6-[4-(4-[4-[4-carboxy-3-(6-hydroxy-3-oxo-3H-xanthen-9-yl)benzoyl]piperazin-1-yl]phenyl)piperazin-1-yl]pyridine-3-carbony]amino)-1-carboxypentyl]carbamoyl]-L-glutamic acid
-
N-[[(1S)-5-acetamido-1-carboxypentyl]carbamoyl]-L-glutamic acid
-
N-[[(1S)-5-acetamido-1-carboxypentyl]carbamoyl]-L-glutamic acid
-
N-[[(1S)-5-[acetyl[(4-bromophenyl)methyl]amino]-1-carboxypentyl]carbamoyl]-L-glutamic acid
-
N-[[(1S)-5-[acetyl[(4-bromophenyl)methyl]amino]-1-carboxypentyl]carbamoyl]-L-glutamic acid
-
Quisqualic acid
-
-
Quisqualic acid
-
0.00048 mM, 50% inhibition
VA-033
-
i.e. 2-([(benzyloxy)phosphonyl]methyl)pentanedioic acid
VA-033
-
i.e. 2-([(benzyloxy)phosphonyl]methyl)pentanedioic acid
additional information
-
the androgen receptor negatively regulates the enzyme expression
-
additional information
-
design of urea-based NAAG peptidase-specific inhibitors, IC50 values of the stereoisomers, inhibition strategies, overview, inhibitors are used in therapy of neurological disorders, overview, construction of a human traumatic brain injury, TBI, to test inhibitor effects, overview
-
additional information
-
GCPIII enzyme-inhibitor interactions and the architecture of the S1' pocket, overview
-
additional information
-
design and synthesis of a series of glutamate-urea-X heterodimeric inhibitors of PSMA, where X is epsilon-N-(o-I, m-I, p-I, p-Br, o-Cl, m-Cl, p-Cl, p-F, H)-benzyl-Lys and epsilon-(p-I, p-Br, p-Cl, p-F, H)-phenylureido-Lys, overview. PSMA binding of the benzyllysine series is significantly affected by the nature of the halogen substituent. The halogen atom has little affect on the binding affinity in the para-substituted phenylureido-Lys series
-
additional information
-
inhibitor in vivo distribution studies in mice bearing either PSMA-positive LNCaP or PSMA-negative PC-3 tumors, overview
-
additional information
-
phosphoramidate peptidomimetic PSMA inhibitors are capable of both cell-surface labeling of prostate cancer cells and intracellular delivery. Use of a PSMA inhibitor-conjugate of pyropheophorbide-a, i.e. Ppa-conjugate 2, for targeted photodynamic therapy to achieve apoptosis in PSMA and LNCaP cells, overview
-
additional information
pharmacophore analysis followed by QSAR studies proposes a N-acetyl aspartyl glutamate-analogue as the most potent inhibitor of the enzyme, effective across all the genetic variants of glutamate carboxypeptidase II. This molecule satisfies Lipinski rule of five and rule of three for drug-likeliness. Being a N-acetyl aspartyl glutamate-analogue, this molecule might confer neuroprotection by inhibiting glutamatergic neurotransmission mediated by N-acetylated alpha-linked acidic dipeptidase (NAALADase), a splice variant of glutamate carboxypeptidase II
-
additional information
-
the androgen receptor negatively regulates the enzyme expression
-
additional information
-
N-[N-((S)-1,3-dicarboxypropyl)carbamoyl]-S-3-iodo-L-tyrosine, i.e. DCIT, is a potent antagonist of the enzyme activity
-
additional information
-
glutamate receptor antagonists reduce the enzyme activity in vivo, overview
-
additional information
-
not inhibitory are pepstatin, iodoacetamide, amastatin
-
additional information
-
N-acetyl-L-Asp-D-Glu
-
additional information
-
N-acetyl-L-Asp-D-Glu
-
additional information
-
GCPII inhibitors are attractive candidates for clinical treatment trials in amylotrophic lateral sclerosis
-
additional information
-
design of urea-based NAAG peptidase-specific inhibitors, inhibition strategies, overview, construction of a stroke rat model and traumatic brain injury, TBI, to test inhibitor effects, overview
-
additional information
-
N-[N-((S)-1,3-dicarboxypropyl)carbamoyl]-S-3-iodo-L-tyrosine, i.e. DCIT, is a potent antagonist of the enzyme activity
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
0.00052 - 0.00058
(2S)-2-amino-3-(3,5-dioxo-1,2,4-oxadiazolidin-2-yl)propanoic acid
0.000008
(2S)-2-[([[(1S)-1,3-dicarboxypropyl]amino]carbonyl)amino]pentanedioic acid
-
pH 7.4, 37°C
0.000003
(2S)-2-[([[(1S)-1-carboxy-2-(4-hydroxyphenyl)ethyl]amino]carbonyl)amino]pentanedioic acid
-
pH 7.4, 37°C
0.000012
(2S)-2-[([[(1S)-1-carboxy-2-phenylethyl]amino]carbonyl)amino]pentanedioic acid
-
pH 7.4, 37°C
0.0000009
(2S)-2-[([[(1S)-1-carboxy-3-(1H-tetrazol-5-yl)propyl]amino]carbonyl)amino]pentanedioic acid
-
pH 7.4, 37°C
0.0000149
(2S)-2-[([[(1S)-1-carboxy-3-(2H-tetrazol-5-yl)propyl]amino]carbonyl)amino]-4-(2H-tetrazol-5-yl)butanoic acid
-
pH 7.4, 37°C
0.000335
(2S)-2-[([[(1S)-3-carboxy-1-(2H-tetrazol-5-yl)propyl]amino]carbonyl)amino]pentanedioic acid
-
pH 7.4, 37°C
0.0000059
(2S)-2-[([[(S)-carboxy(4-hydroxyphenyl)methyl]amino]carbonyl)amino]pentanedioic acid
-
pH 7.4, 37°C
0.0000053
(2S)-2-[[([(1S)-1-carboxy-3-[1-(2-cyanoethyl)-1H-tetrazol-5-yl]propyl]amino)carbonyl]amino]pentanedioic acid
-
pH 7.4, 37°C
0.002711
(2S)-2-[[([(1S)-3-carboxy-1-[2-(2-cyanoethyl)-2H-tetrazol-5-yl]propyl]amino)carbonyl]amino]pentanedioic acid
-
pH 7.4, 37°C
0.000104
(2S)-2-[[butyl(hydroxy)phosphorothioyl]amino]pentanedioic acid
-
pH 7.4, 37°C
0.00109
(2S)-2-[[ethyl(hydroxy)phosphorothioyl]amino]pentanedioic acid
-
pH 7.4, 37°C
0.000719
(2S)-2-[[hydroxy(methyl)phosphorothioyl]amino]pentanedioic acid
-
pH 7.4, 37°C
0.00639
(2S)-2-[[hydroxy(phenyl)phosphorothioyl]amino]pentanedioic acid
-
pH 7.4, 37°C
0.0146
(2S)-2-[[hydroxy(phenyl)phosphorothioyl]oxy]pentanedioic acid
-
pH 7.4, 37°C
0.00111
(2S)-2-[[hydroxy(phenyl)phosphoryl]amino]pentanedioic acid
-
pH 7.4, 37°C
0.000095 - 0.0000953
(2S,2'S,4R)-4-benzyl-N,N'-carbonyldiglutamic acid
0.000392
(2S,2'S,4R,4'R)-4,4'-dibenzyl-N,N'-carbonyldiglutamic acid
0.00129
(2S,2'S,4R,4'R)-N,N'-carbonyl-4,4'-dimethyldiglutamic acid
-
pH 7.4, 37°C, recombinant enzyme
0.000014 - 0.0000144
(2S,2'S,4S)-N,N'-carbonyl-4-methyldiglutamic acid
0.00111
(2S,2'S,4S,4'S)-N,N'-carbonyl-4,4'-dimethyldiglutamic acid
-
pH 7.4, 37°C, recombinant enzyme
0.0000129 - 0.0000346
(2S,3'S)-[[(3'-amino-3'-carboxy-propyl)-hydroxyphosphinoyl]methyl]-pentanedioic acid
0.001285
(2S,4R)-2-[([[(1S,3R)-1,3-dicarboxybutyl]amino]carbonyl)amino]-4-methylpentanedioic acid
-
pH 7.4, 37°C
0.001109
(2S,4S)-2-[([[(1S,3S)-1,3-dicarboxybutyl]amino]carbonyl)amino]-4-methylpentanedioic acid
-
pH 7.4, 37°C
0.004388
(4S)-4-[([[(1S)-3-carboxy-1-(2H-tetrazol-5-yl)propyl]amino]carbonyl)amino]-4-(2H-tetrazol-5-yl)butanoic acid
-
pH 7.4, 37°C
0.000000003
(S)-2-(3-((S)-1-carboxy-(4-iodobenzamido)pentyl)ureido)pentanedioic acid
pH and temperature not specified in the publication
0.0000015
(S)-2-(3-((S)-1-carboxy-2-(4-hydroxy-3-iodophenyl)ethyl)ureido)pentanedioic acid
-
-
0.00000024
(S)-2-(3-((S)-1-carboxy-5-(3-(4-iodophenyl)ureido)pentyl)ureido)pentanedioic acid
-
-
0.0000046
(S)-2-(3-((S)-1-carboxy-5-(4-iodobenzylamino)pentyl)ureido)pentanedioic acid
-
-
0.000000049
(S)-2-(3-((S)-5-(6-(4-(4-(4-acetylpiperazin-1-yl)phenyl)piperazin-1-yl)-N-(4-bromobenzyl)nicotinamido)-1-carboxypentyl)ureido)-pentanedioic acid
pH and temperature not specified in the publication
0.000000071
(S)-2-(3-((S)-5-(6-(4-(4-(4-acetylpiperazin-1-yl)phenyl)piperazin-1-yl)nicotinamido)-1-carboxypentyl)ureido)pentanedioic acid
pH and temperature not specified in the publication
0.0000000086
(S)-2-(3-((S)-5-(N-(4-bromobenzyl)-6-(4-(4-(4-(4-carboxy-3-(6-hydroxy-3-oxo-3H-xanthen-9-yl)benzoyl)piperazin-1-yl)phenyl)-piperazin-1-yl)nicotinamido)-1-carboxypentyl)ureido)pentanedioic acid
pH and temperature not specified in the publication
0.00000011
(S)-2-(3-((S)-5-(N-(4-bromobenzyl)-6-(4-(4-(4-(41-oxo-45-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)-4,7,10,13,16,19,22,25,28,31,34,37-dodecaoxa-40-azapentatetracontan-1-oyl)piperazin-1-yl)phenyl)piperazin-1-yl)nicotinamido)-1-carboxypentyl)ureido)pentanedioic acid
pH and temperature not specified in the publication
0.000003
(S)-2-[3-((S)-1-carboxy-2-(4-hydroxyphenyl)ethyl)ureido]pentanedioic acid
-
pH 7.4, 37°C, recombinant enzyme
0.000012
(S)-2-[3-((S)-1-carboxy-2-phenylethyl)ureido]pentanedioic acid
-
pH 7.4, 37°C, recombinant enzyme
0.0000009
(S)-2-[3-((S)-1-carboxy-3-(1H-tetrazol-5-yl)propyl)ureido]pentanedioic acid
-
pH 7.4, 37°C, recombinant enzyme
0.0000053
(S)-2-[3-((S)-1-carboxy-3-[1-(2-cyanoethyl)-1H-tetrazol-5-yl]propyl)ureido]pentanedioic acid
-
pH 7.4, 37°C, recombinant enzyme
0.000335
(S)-2-[3-((S)-3-carboxy-1-(1H-tetrazol-5-yl)propyl)ureido]pentanedioic acid
-
pH 7.4, 37°C, recombinant enzyme
0.00271
(S)-2-[3-((S)-3-carboxy-1-[1-(2-cyanoethyl)-1H-tetrazol-5-yl]propyl)ureido]pentanedioic acid
-
pH 7.4, 37°C, recombinant enzyme
0.0000059
(S)-2-[3-((S)-alpha-carboxy-4-hydroxybenzyl)ureido]pentanedioic acid
-
pH 7.4, 37°C, recombinant enzyme
0.0000021
(S)-2-[3-((S)-alpha-carboxybenzyl)ureido]pentanedioic acid
0.000008
(S)-2-[3-(S)-(1,3-dicarboxypropyl)ureido]pentanedioinc acid
-
pH 7.4, 37°C, recombinant enzyme
0.00443 - 0.004434
(S,S)-4,4'-bis[1-(2-cyanoethyl)-1H-tetrazol-5-yl]-2,2'-ureylenedibutyric acid
1
(S,S)-4,4'-bis[1-(2-cyanoethyl)-1H-tetrazol-5-yl]-4,4'-ureylenedibutyric acid
-
above, pH 7.4, 37°C, recombinant enzyme
0.000015
(S,S)-4,4'-di-(1H-tetrazol-5-yl)-2,2'-ureylenedibutyric acid
-
pH 7.4, 37°C, recombinant enzyme
0.00439
(S,S)-4,4'-di-(1H-tetrazol-5-yl)-4,4'-ureylenedibutyric acid
-
pH 7.4, 37°C, recombinant enzyme
0.000939
(S,S)-N,N'-carbonyl-2,2'-dimethyldiglutamic acid
0.00003
2-(3-mercaptopropyl)-pentanedioic acid
-
-
0.0000002 - 0.0000014
2-(phosphonomethyl)-pentanedioic acid
0.00000028
2-(phosphonomethyl)pentandioic acid
pH and temperature not specified in the publication
0.0000002 - 0.0000014
2-(phosphonomethyl)pentanedioic acid
0.00023 - 0.00102
2-amino-3-(3,5-dioxo[1,2,4]oxadiazolidin-2-yl)propionic acid
0.000000018
DKFZ-PSMA-11
pH and temperature not specified in the publication
0.019
glutathione
-
i.e. gamma-Glu-Cys-Gly
0.00000001
N-([(1S)-1-carboxy-5-([(4-iodophenyl)carbonyl]amino)pentyl]carbamoyl)-L-glutamic acid
pH not specified in the publication, temperature not specified in the publication
0.0000053
N-2-([(1S)-1-carboxy-2-(furan-2-yl)ethyl]carbamoyl)-N-6-(4-iodobenzoyl)-L-lysine
pH not specified in the publication, temperature not specified in the publication
0.0000053
N-2-([(1S)-1-carboxybut-3-yn-1-yl]carbamoyl)-N-6-(4-iodobenzoyl)-L-lysine
pH not specified in the publication, temperature not specified in the publication
0.036
N-Acetyl-Glu-Asp
-
-
0.00031
N-Acetyl-Glu-Glu
-
-
0.00054
N-Acetyl-L-Asp-L-Glu
-
-
0.016 - 0.024
N-[4-carboxy-3-(carboxymethyl)-3-hydroxybutanoyl]-L-glutamic acid
0.0000149
N-[[(1S)-1-carboxy-3-(1H-tetrazol-5-yl)propyl]carbamoyl]-L-glutamic acid
-
pH 7.4, 37°C
0.00000058 - 0.0000059
N-[[(1S)-1-carboxy-3-methylbutyl]carbamoyl]-L-glutamic acid
0.000000017 - 0.000000028
N-[[(1S)-1-carboxy-5-(4-iodobenzamido)pentyl]carbamoyl]-L-glutamic acid
0.000000018 - 0.0000001
N-[[(1S)-1-carboxy-5-([5-[3-(3-[[[2-[[[5-(2-carboxyethyl)-2-hydroxyphenyl]methyl](carboxymethyl)amino]ethyl](carboxymethyl)amino]methyl]-4-hydroxyphenyl)propanamido]pentanoyl]amino)pentyl]carbamoyl]-L-glutamic acid
0.000000021 - 0.000000049
N-[[(1S)-5-([(4-bromophenyl)methyl][6-[4-(4-[4-[4-carboxy-3-(6-hydroxy-3-oxo-3H-xanthen-9-yl)benzoyl]piperazin-1-yl]phenyl)piperazin-1-yl]pyridine-3-carbony]amino)-1-carboxypentyl]carbamoyl]-L-glutamic acid
0.00000017 - 0.00000066
N-[[(1S)-5-acetamido-1-carboxypentyl]carbamoyl]-L-glutamic acid
0.00000005 - 0.00000068
N-[[(1S)-5-[acetyl[(4-bromophenyl)methyl]amino]-1-carboxypentyl]carbamoyl]-L-glutamic acid
0.00000058
N-[[[(1S)-1-carboxy-3-methylbutyl]amino]carbonyl]-L-glutamic acid
pH and temperature not specified in the publication
0.042
Serine O-sulfate
-
-
0.00052
(2S)-2-amino-3-(3,5-dioxo-1,2,4-oxadiazolidin-2-yl)propanoic acid
37°C, pH 7.4
0.00058
(2S)-2-amino-3-(3,5-dioxo-1,2,4-oxadiazolidin-2-yl)propanoic acid
37°C, pH 7.4
0.000095
(2S,2'S,4R)-4-benzyl-N,N'-carbonyldiglutamic acid
-
pH 7.4, 37°C, recombinant enzyme
0.0000953
(2S,2'S,4R)-4-benzyl-N,N'-carbonyldiglutamic acid
-
pH 7.4, 37°C
0.000392
(2S,2'S,4R,4'R)-4,4'-dibenzyl-N,N'-carbonyldiglutamic acid
-
pH 7.4, 37°C
0.000392
(2S,2'S,4R,4'R)-4,4'-dibenzyl-N,N'-carbonyldiglutamic acid
-
pH 7.4, 37°C, recombinant enzyme
0.000014
(2S,2'S,4S)-N,N'-carbonyl-4-methyldiglutamic acid
-
pH 7.4, 37°C, recombinant enzyme
0.0000144
(2S,2'S,4S)-N,N'-carbonyl-4-methyldiglutamic acid
-
pH 7.4, 37°C
0.0000129
(2S,3'S)-[[(3'-amino-3'-carboxy-propyl)-hydroxyphosphinoyl]methyl]-pentanedioic acid
-
GCPII
0.0000346
(2S,3'S)-[[(3'-amino-3'-carboxy-propyl)-hydroxyphosphinoyl]methyl]-pentanedioic acid
-
GCPIII
0.0000021
(S)-2-[3-((S)-alpha-carboxybenzyl)ureido]pentanedioic acid
-
pH 7.4, 37°C
0.0000021
(S)-2-[3-((S)-alpha-carboxybenzyl)ureido]pentanedioic acid
-
pH 7.4, 37°C, recombinant enzyme
0.00443
(S,S)-4,4'-bis[1-(2-cyanoethyl)-1H-tetrazol-5-yl]-2,2'-ureylenedibutyric acid
-
pH 7.4, 37°C, recombinant enzyme
0.004434
(S,S)-4,4'-bis[1-(2-cyanoethyl)-1H-tetrazol-5-yl]-2,2'-ureylenedibutyric acid
-
pH 7.4, 37°C
0.000939
(S,S)-N,N'-carbonyl-2,2'-dimethyldiglutamic acid
-
pH 7.4, 37°C
0.000939
(S,S)-N,N'-carbonyl-2,2'-dimethyldiglutamic acid
-
pH 7.4, 37°C, recombinant enzyme
0.0000002
2-(phosphonomethyl)-pentanedioic acid
-
-
0.0000003
2-(phosphonomethyl)-pentanedioic acid
-
-
0.0000014
2-(phosphonomethyl)-pentanedioic acid
-
pH 7.4, 37°C, recombinant enzyme
0.0000002
2-(phosphonomethyl)pentanedioic acid
-
pH 7.4, 37°C
0.00000026
2-(phosphonomethyl)pentanedioic acid
37°C, pH 7.4
0.0000003
2-(phosphonomethyl)pentanedioic acid
-
pH and temperature not specified in the publication
0.0000003
2-(phosphonomethyl)pentanedioic acid
pH and temperature not specified in the publication
0.00000056
2-(phosphonomethyl)pentanedioic acid
37°C, pH 7.4
0.0000014
2-(phosphonomethyl)pentanedioic acid
-
pH 7.4, 37°C
0.00023
2-amino-3-(3,5-dioxo[1,2,4]oxadiazolidin-2-yl)propionic acid
-
GCPIII
0.00102
2-amino-3-(3,5-dioxo[1,2,4]oxadiazolidin-2-yl)propionic acid
-
GCPII
0.27
L-Glu
-
GCPIII
0.016
N-[4-carboxy-3-(carboxymethyl)-3-hydroxybutanoyl]-L-glutamic acid
37°C, pH 7.4
0.024
N-[4-carboxy-3-(carboxymethyl)-3-hydroxybutanoyl]-L-glutamic acid
37°C, pH 7.4
0.00000058
N-[[(1S)-1-carboxy-3-methylbutyl]carbamoyl]-L-glutamic acid
37°C, pH 7.4
0.0000059
N-[[(1S)-1-carboxy-3-methylbutyl]carbamoyl]-L-glutamic acid
37°C, pH 7.4
0.000000017
N-[[(1S)-1-carboxy-5-(4-iodobenzamido)pentyl]carbamoyl]-L-glutamic acid
37°C, pH 7.4
0.000000028
N-[[(1S)-1-carboxy-5-(4-iodobenzamido)pentyl]carbamoyl]-L-glutamic acid
37°C, pH 7.4
0.000000018
N-[[(1S)-1-carboxy-5-([5-[3-(3-[[[2-[[[5-(2-carboxyethyl)-2-hydroxyphenyl]methyl](carboxymethyl)amino]ethyl](carboxymethyl)amino]methyl]-4-hydroxyphenyl)propanamido]pentanoyl]amino)pentyl]carbamoyl]-L-glutamic acid
37°C, pH 7.4
0.0000001
N-[[(1S)-1-carboxy-5-([5-[3-(3-[[[2-[[[5-(2-carboxyethyl)-2-hydroxyphenyl]methyl](carboxymethyl)amino]ethyl](carboxymethyl)amino]methyl]-4-hydroxyphenyl)propanamido]pentanoyl]amino)pentyl]carbamoyl]-L-glutamic acid
37°C, pH 7.4
0.000000021
N-[[(1S)-5-([(4-bromophenyl)methyl][6-[4-(4-[4-[4-carboxy-3-(6-hydroxy-3-oxo-3H-xanthen-9-yl)benzoyl]piperazin-1-yl]phenyl)piperazin-1-yl]pyridine-3-carbony]amino)-1-carboxypentyl]carbamoyl]-L-glutamic acid
37°C, pH 7.4
0.000000049
N-[[(1S)-5-([(4-bromophenyl)methyl][6-[4-(4-[4-[4-carboxy-3-(6-hydroxy-3-oxo-3H-xanthen-9-yl)benzoyl]piperazin-1-yl]phenyl)piperazin-1-yl]pyridine-3-carbony]amino)-1-carboxypentyl]carbamoyl]-L-glutamic acid
37°C, pH 7.4
0.00000017
N-[[(1S)-5-acetamido-1-carboxypentyl]carbamoyl]-L-glutamic acid
37°C, pH 7.4
0.00000066
N-[[(1S)-5-acetamido-1-carboxypentyl]carbamoyl]-L-glutamic acid
37°C, pH 7.4
0.00000005
N-[[(1S)-5-[acetyl[(4-bromophenyl)methyl]amino]-1-carboxypentyl]carbamoyl]-L-glutamic acid
37°C, pH 7.4
0.00000068
N-[[(1S)-5-[acetyl[(4-bromophenyl)methyl]amino]-1-carboxypentyl]carbamoyl]-L-glutamic acid
37°C, pH 7.4
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
0.0000002
(2S)-2-([hydroxy[2-(4-hydroxyphenyl)ethoxy]phosphoryl]methyl)pentanedioic acid
Homo sapiens
-
-
0.0003
(2S)-2-([[2-(4-fluorophenyl)ethoxy](hydroxy)phosphoryl]methyl)pentanedioic acid
Homo sapiens
-
-
0.0000007
(2S)-2-([[2-(4-[[N-(tert-butoxycarbonyl)glycyl]amino]phenyl)ethoxy](hydroxy)phosphoryl]methyl)pentanedioic acid
Homo sapiens
-
-
0.0000001
(2S)-2-[[(2-[4-[(tert-butoxycarbonyl)amino]phenyl]ethoxy)(hydroxy)phosphoryl]methyl]pentanedioic acid
Homo sapiens
-
-
0.0000008
(2S)-2-[[hydroxy(2-phenylethoxy)phosphoryl]methyl]pentanedioic acid
Homo sapiens
-
-
0.000004
(2S)-2-[[hydroxy(3-phenylpropoxy)phosphoryl]methyl]pentanedioic acid
Homo sapiens
-
-
0.000004
(2S)-2-[[[2-[4-(acetylamino)phenyl]ethoxy](hydroxy)phosphoryl]methyl]pentanedioic acid
Homo sapiens
-
-
0.000018
(9S,13S)-1-(3-iodophenyl)-3,11-dioxo-2,4,10,12-tetraazapentadecane-9,13,15-tricarboxylic acid
Homo sapiens
-
-
0.0014
(R)-2-(hydroxypentafluorophenylmethyl-phosphinoylmethyl)pentanedioic acid
Homo sapiens
-
40fold less potent than the S-isomer, IC50: 0.0014 mM
0.00003
(R)-2-(phosphonomethyl)-pentanedioic acid
Homo sapiens
-
less potent than the S-isomer, IC50: 0.000030 mM
0.000017
(S)-2-(3-((R)-1-carboxy-(2-methylthio)ethyl)ureido)pentanedioic acid
Homo sapiens
-
0.000014
(S)-2-(3-((R)-1-carboxy-2-(4-fluorobenzylthio)ethyl)ureido)pentanedioic acid
Homo sapiens
-
0.00000006
(S)-2-(3-((S)-1-carboxy-(4-iodobenzamido)pentyl)ureido)pentanedioic acid
Homo sapiens
-
0.0000005
(S)-2-(3-((S)-1-carboxy-2-(4-hydroxy-3-iodophenyl)ethyl)ureido)pentanedioic acid
Homo sapiens
-
0.000245
(S)-2-(3-((S)-1-carboxy-5-(2-chlorobenzylamino)pentyl)ureido)pentanedioic acid
Homo sapiens
-
-
0.000037
(S)-2-(3-((S)-1-carboxy-5-(2-iodobenzylamino)pentyl)ureido)-pentanedioic acid
Homo sapiens
-
-
0.000002
(S)-2-(3-((S)-1-carboxy-5-(3-(4-bromophenyl)ureido)pentyl)ureido)pentanedioic acid
Homo sapiens
-
-
0.000004
(S)-2-(3-((S)-1-carboxy-5-(3-(4-chlorophenyl)ureido)pentyl)ureido)pentanedioic acid
Homo sapiens
-
-
0.000003
(S)-2-(3-((S)-1-carboxy-5-(3-(4-fluorophenyl)ureido)pentyl)ureido)pentanedioic acid
Homo sapiens
-
-
0.00001
(S)-2-(3-((S)-1-carboxy-5-(3-(4-iodophenyl)ureido)pentyl)ureido)pentanedioic acid
Homo sapiens
-
-
0.000277
(S)-2-(3-((S)-1-carboxy-5-(3-chlorobenzylamino)pentyl)ureido)pentanedioic acid
Homo sapiens
-
-
0.000443
(S)-2-(3-((S)-1-carboxy-5-(3-iodobenzylamino)pentyl)ureido)-pentanedioic acid
Homo sapiens
-
-
0.000012
(S)-2-(3-((S)-1-carboxy-5-(3-phenylureido)pentyl)ureido)pentanedioic acid
Homo sapiens
-
-
0.000043
(S)-2-(3-((S)-1-carboxy-5-(4-bromobenzylamino)pentyl)ureido)pentanedioic acid
Homo sapiens
-
-
0.000002
(S)-2-(3-((S)-1-carboxy-5-(4-chlorobenzylamino)pentyl)ureido)pentanedioic acid
Homo sapiens
-
-
0.0012
(S)-2-(3-((S)-1-carboxy-5-(4-fluorobenzylamino)pentyl)ureido)pentanedioic acid
Homo sapiens
-
-
0.000022
(S)-2-(3-((S)-1-carboxy-5-(4-iodobenzylamino)pentyl)ureido)-pentanedioic acid
Homo sapiens
-
-
0.00001
(S)-2-(3-((S)-1-carboxy-5-(4-iodophenylsulfonamido)pentyl)-ureido)pentanedioic acid
Homo sapiens
-
-
0.000154
(S)-2-(3-((S)-1-carboxy-5-(naphthalen-1-ylmethylamino)pentyl)-ureido)pentanedioic acid
Homo sapiens
-
-
0.00296
(S)-2-(3-((S)-5-(benzylamino)-1-carboxypentyl)ureido)pentanedioic acid
Homo sapiens
-
-
0.000498
(S)-2-(3-((S)-5-amino-1-carboxypentyl)ureido)pentanedioic acid
Homo sapiens
-
-
0.003
(S)-2-(3-(4-iodobenzyl)ureido)pentanedioic acid
Homo sapiens
-
-
0.000034
(S)-2-(hydroxypentafluorophenylmethyl-phosphinoylmethyl)pentanedioic acid
Homo sapiens
-
40fold more potent than the R-isomer, IC50: 0.000034 mM
0.0000001
(S)-2-(phosphonomethyl)-pentanedioic acid
Homo sapiens
-
more potent than the R-isomer, IC50: 0.0000001 mM
0.000029
(t-Bu)Cys-PSI[C-O]-Glu
Rattus norvegicus
-
IC50: 29 nM
0.0017
2-(2-carboxy-5-mercaptopentyl)benzoic acid
Homo sapiens
-
IC50: 1700 nM
0.0022
2-(3-carbamoylbenzyl)-5-mercaptopentanoic acid
Homo sapiens
-
IC50: 2200 nM
0.015
2-(3-carboxybenyl)succinic acid
Homo sapiens
-
IC50: 0.015 mM
0.0018
2-(3-cyanobenzyl)-5-mercaptopentanoic acid
Homo sapiens
-
IC50: 1800 nM
0.000508
2-(3-hydroxybenzyl)-3-phosphonopropanoic acid
Rattus norvegicus
-
IC50: 508 nM
0.00009
2-(3-mercaptopropyl)-pentanedioic acid
Homo sapiens
-
i.e. 2-MPPA, IC50: 90 nM
0.00009
2-(3-mercaptopropyl)pentanedioic acid
Rattus norvegicus
-
IC50: 90 nM. Orally bioavailable in rats
0.000175
2-(phosphonomethyl)-4-(5H-tetrazol-5-yl)butanoic acid
Rattus norvegicus
-
IC50: 175 nM
0.00000674 - 0.000094
2-(phosphonomethyl)-pentanedioic acid
0.000185
2-(phosphonomethyl)hexanedioic acid
Rattus norvegicus
-
IC50: 185 nM
0.000185
2-(phosphonomethyl)hexanoic acid
Rattus norvegicus
-
IC50: 185 nM
0.0000003 - 0.0000051
2-(phosphonomethyl)pentanedioic acid
0.0022
2-(phosphonomethyl)succinic acid
Rattus norvegicus
-
IC50: 2200 nM
0.000055
2-([hydroxy[3-(trifluoromethyl)benzyl]phosphoryl]methyl)pentanedioic acid
Rattus norvegicus
-
IC50: 55 nM
0.000055
2-([hydroxy[hydroxy(phenyl)methyl]phosphoryl]methyl)pentanedioic acid
Rattus norvegicus
-
IC50: 55 nM
0.00001
2-([hydroxy[hydroxy(pyridin-4-yl)methyl]phosphoryl]methyl)pentanedioic acid
Rattus norvegicus
-
IC50: 10 nM
0.000548
2-benzyl-3-phosphonopropanoic acid
Rattus norvegicus
-
IC50: 548 nM
0.0014
2-benzyl-5-mercaptopentanoic acid
Homo sapiens
-
IC50: 1400 nM
0.000003
2-[(hydroxy[[(4-methoxyphenyl)amino]methyl]phosphoryl)methyl]pentanedioic acid
Rattus norvegicus
-
IC50: 3 nM
0.0000005
2-[[(2,4-dicarboxybutyl)(hydroxy)phosphoryl]methyl]pentanedioic acid
Rattus norvegicus
-
IC50: 0.5 nM
0.000002
2-[[(2-carboxy-3-phenylpropyl)(hydroxy)phosphoryl]methyl]pentanedioic acid
Rattus norvegicus
-
IC50: 2 nM
0.000002
2-[[(2-carboxy-4-phenylbutyl)(hydroxy)phosphoryl]methyl]pentanedioic acid
Rattus norvegicus
-
IC50: 2 nM
0.000001
2-[[(2-carboxyethyl)(hydroxy)phosphoryl]methyl]pentanedioic acid
Rattus norvegicus
-
IC50: 1 nM
0.0000015
2-[[(2-carboxypropyl)(hydroxy)phosphoryl]methyl]pentanedioic acid
Rattus norvegicus
-
IC50: 1.5 nM
0.000156
2-[[(2-fluorobenzyl)(hydroxy)phosphoryl]methyl]pentanedioic acid
Rattus norvegicus
-
IC50: 156 nM
0.000049
2-[[(3,5-difluorobenzyl)(hydroxy)phosphoryl]methyl]pentanedioic acid
Rattus norvegicus
-
IC50: 49 nM
0.000143
2-[[(3-aminobenzyl)(hydroxy)phosphoryl]methyl]pentanedioic acid
Rattus norvegicus
-
IC50: 143 nM
0.00007
2-[[(3-fluorobenzyl)(hydroxy)phosphoryl]methyl]pentanedioic acid
Rattus norvegicus
-
IC50: 70 nM
0.000064
2-[[(4-fluorobenzyl)(hydroxy)phosphoryl]methyl]pentanedioic acid
Rattus norvegicus
-
IC50: 64 nM
0.000004
2-[[(anilinomethyl)(hydroxy)phosphoryl]methyl]pentanedioic acid
Rattus norvegicus
-
IC50: 4 nM
0.000053 - 0.00007
2-[[benzyl(hydroxy)phosphoryl]methyl]pentanedioic acid
0.000149 - 0.00015
2-[[hydroxy(2-phenylethyl)phosphoryl]methyl]pentanedioic acid
0.000059
2-[[hydroxy(3-nitrobenzyl)phosphoryl]methyl]pentanedioic acid
Rattus norvegicus
-
IC50 59 nM
0.00023
2-[[hydroxy(3-phenylpropyl)phosphoryl]methyl]pentanedioic acid
Rattus norvegicus
-
IC50: 230 nM
0.00009
2-[[hydroxy(4-methoxybenzyl)phosphoryl]methyl]pentanedioic acid
Rattus norvegicus
-
IC50: 90 nM
0.000068
2-[[hydroxy(4-methylbenzyl)phosphoryl]methyl]pentanedioic acid
Rattus norvegicus
-
IC50: 68 nM
0.000082
2-[[hydroxy(pentafluorobenzyl)phosphoryl]methyl]pentanedioic acid
Rattus norvegicus
-
IC50: 82 nM. Significantly prevents neurodegeneration in a middle cerebral artery occlusion model of cerebral ischemia. In the chronic constrictive model of neuropathic pain, the inhibitor sifnificantly attenuats the hypersensitivity observed with saline-
0.00293
2-[[hydroxy(phenyl)phosphoryl]methyl]pentanedioic acid
Rattus norvegicus
-
IC50: 2930 nM
0.00036 - 0.00056
2-[[hydroxy(propyl)phosphoryl]methyl]pentanedioic acid
0.000016
2-[[[(3-fluorophenyl)(hydroxy)methyl](hydroxy)phosphoryl]methyl]pentanedioic acid
Rattus norvegicus
-
IC50: 16 nM
0.000059
2-[[[(benzylamino)methyl](hydroxy)phosphoryl]methyl]pentanedioic acid
Rattus norvegicus
-
IC50: 59 nM
0.000055
2-[[[3,5-bis(trifluoromethyl)benzyl](hydroxy)phosphoryl]methyl]pentanedioic acid
Rattus norvegicus
-
IC50: 55 nM
0.000095
2-[[[3-(benzyloxy)-2-methyl-3-oxopropyl](hydroxy)phosphoryl]methyl]pentanedioic acid
Rattus norvegicus
-
IC50: 95 nM
0.000003
2-{[2-Carboxy-3-(4-methoxy-phenylamino)-propyl]-hydroxy-phosphinoylmethyl}-pentanedioic acid
Rattus norvegicus
-
IC50: 3 nM
0.000014
3-(1-carboxy-4-mercaptobutoxy)benzoic acid
Homo sapiens
-
IC50: 14 nM
0.00064
3-(2-carbamoyl-5-mercaptopentyl)benzoic acid
Homo sapiens
-
IC50: 640 nM
0.015
3-(2-carboxy-3-hydroxycarbamoylpropyl)benzoic acid
Homo sapiens
-
IC50: 0.015 mM
0.00012
3-(2-carboxy-3-phosphonopropyl)benzoic acid
Homo sapiens
-
IC50: 120 nM
0.000015
3-(2-carboxy-5-mercaptopentyl)benzoic acid
Homo sapiens
-
IC50: 15 nM
0.0027
3-(2-carboxy-5-mercaptopentyl)benzoic acid methyl ester
Homo sapiens
-
IC50: 2700 nM
0.02
3-(2-carboxy-5-mercaptosulfanylpentyl)benzoic acid
Homo sapiens
-
IC50: 0.02 mM
0.02
3-(2-carboxy-5-tritylsulfanylpentyl)benzoic acid
Homo sapiens
-
IC50: 0.02 mM
0.002
3-(2-oxotetrahydro-thiopyran-3-yl)propionic acid
Rattus norvegicus
-
pH not specified in the publication, temperature not specified in the publication
0.00073
3-(5-mercapto-2-methoxycarbonylpentyl)benzoic acid
Homo sapiens
-
IC50: 730 nM
0.000032
3-[(1-carboxy-4-mercaptobutyl)thio]benzoic acid
Homo sapiens
-
IC50: 32 nM
0.0024
3-[2-carboxy-3-(hydroxypentafluorophenylmethylphosphinoyl)propyl]benzoic acid
Homo sapiens
-
IC50: 2400 nM
0.000063
4-(2-carboxy-5-mercaptopentyl)benzoic acid
Homo sapiens
-
IC50: 63 nM
0.000508
4-(3-hydroxyphenyl)-2-(phosphonomethyl)butanoic acid
Rattus norvegicus
-
IC50: 508 nM
0.000335
4-cyano-2-(phosphonomethyl)butanoic acid
Rattus norvegicus
-
IC50: 335 nM
0.000199
4-phenyl-2-(phosphonomethyl)butanoic acid
Rattus norvegicus
-
IC50: 199 nM
0.0461
Asp-PSI[C-O-S]-Glu
Rattus norvegicus
-
IC50: 0.0461 mM
0.0038
Asp-PSI[C-O]-Asp
Rattus norvegicus
-
IC50: 0.0038 mM
0.0000069
Cys-PSI[C-O-S]-Glu
Rattus norvegicus
-
IC50: 6.9 nM
0.000002
diphenyl 2-[[[2-[4-([[7-(diethylamino)-2-oxo-2H-chromen-3-yl]carbamoyl]amino)phenyl]ethoxy](hydroxy)phosphoryl]methyl]pentanedioate
Homo sapiens
-
-
0.000047
Glu-PSI[C-O]-Glu
Rattus norvegicus
-
IC50: 47 nM
0.000016
N-(4-fluorobenzoyl)-L-isoleucyl-O-[[[(1S)-1,3-dicarboxypropyl]amino](hydroxy)phosphoryl]-L-serine
Homo sapiens
37°C, pH 7.4
0.000016
N-(4-fluorobenzoyl)-L-valyl-O-[[[(1S)-1,3-dicarboxypropyl]amino](hydroxy)phosphoryl]-L-serine
Homo sapiens
37°C, pH 7.4
0.000007
N-(tert-butoxycarbonyl)glycyl-N-[4-[2-([[(2S)-2,4-dicarboxybutyl](hydroxy)phosphoryl]oxy)ethyl]phenyl]-L-prolinamide
Homo sapiens
-
-
0.000008
N-(tert-butoxycarbonyl)glycylglycyl-N-[4-[2-([[(2S)-2,4-dicarboxybutyl](hydroxy)phosphoryl]oxy)ethyl]phenyl]glycinamide
Homo sapiens
-
-
0.0018
N-[(2-benzamidoethoxy)(hydroxy)phosphoryl]-L-glutamic acid
Homo sapiens
37°C, pH 7.4
0.00018
N-[hydroxy(4-phenylbutoxy)phosphoryl]-L-glutamic acid
Homo sapiens
37°C, pH 7.4
0.0007
N-[[(2R)-2-benzamido-2-carboxyethoxy](hydroxy)phosphoryl]-L-glutamic acid
Homo sapiens
37°C, pH 7.4
0.000035
N-[[(2S)-2-benzamido-2-carboxyethoxy](hydroxy)phosphoryl]-L-glutamic acid
Homo sapiens
37°C, pH 7.4
0.000014
N-[[(2S)-2-[[(6S)-6-amino-6-carboxy-3-oxohexyl]amino]-2-carboxyethoxy](hydroxy)phosphoryl]-L-glutamic acid
Homo sapiens
37°C, pH 7.4
0.000168
N-[[([1,1'-biphenyl]-4-yl)methoxy](hydroxy)phosphoryl]-L-glutamic acid
Homo sapiens
37°C, pH 7.4
0.000102
pyropheophorbide-a conjugate
Homo sapiens
-
pH 7.4, 37°C
0.000014
S-2-((2-(S-4-(4-18F-fluorobenzamido)-4-carboxybutanamido)-S-2-carboxyethoxy)hydroxyphosphorylamino)-pentanedioic acid
Homo sapiens
-
-
0.00000068
S-2-((2-(S-4-amino-4-carboxybutanamido)-S-2-carboxyethoxy)-hydroxyphosphorylamino)-pentanedioic acid
Homo sapiens
-
-
0.00000674
2-(phosphonomethyl)-pentanedioic acid
Mus musculus
2-PMPA, GCPIII IC50: 94 nM, GCPII IC50: 6.74 nM
0.000094
2-(phosphonomethyl)-pentanedioic acid
Mus musculus
2-PMPA, GCPIII IC50: 94 nM, GCPII IC50: 6.74 nM
0.0000003
2-(phosphonomethyl)pentanedioic acid
Rattus norvegicus
-
IC50: 0.3 nM
0.0000004
2-(phosphonomethyl)pentanedioic acid
Homo sapiens
-
-
0.0000051
2-(phosphonomethyl)pentanedioic acid
Rattus norvegicus
-
IC50: 5.1 nM
0.000053
2-[[benzyl(hydroxy)phosphoryl]methyl]pentanedioic acid
Rattus norvegicus
-
IC50: 53 nM
0.00007
2-[[benzyl(hydroxy)phosphoryl]methyl]pentanedioic acid
Rattus norvegicus
-
IC50: 70 nM
0.000149
2-[[hydroxy(2-phenylethyl)phosphoryl]methyl]pentanedioic acid
Rattus norvegicus
-
IC50: 149 nM
0.00015
2-[[hydroxy(2-phenylethyl)phosphoryl]methyl]pentanedioic acid
Rattus norvegicus
-
IC50: 150 nM
0.00036
2-[[hydroxy(propyl)phosphoryl]methyl]pentanedioic acid
Rattus norvegicus
-
IC50: 360 nM
0.00056
2-[[hydroxy(propyl)phosphoryl]methyl]pentanedioic acid
Rattus norvegicus
-
IC50: 560 nM
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.